Chlorine Dioxide and Chronic Sinusitis: An American Pharmaceutical Patent and Its Research History

In January 2010, American inventor Howard M. Alliger began pursuing patent protection for an approach to treating acute and chronic sinusitis using chlorine dioxide. The invention addressed a persistent challenge in respiratory medicine: inflammation and infection involving the nasal passages and sinus cavities, particularly when symptoms continue despite conventional treatment.

Alliger proposed that chlorine dioxide’s antimicrobial chemistry, combined with its potential interactions with mucus, microbial biofilms, and inflammatory processes, might offer another way to investigate these conditions. The invention eventually became the subject of international patent filings and a United States patent granted in February 2019.

The research history also extends beyond the patent itself. Subsequent scientific literature identifies a commercial chlorine dioxide nasal formulation associated with Sinox Pharma, the company named in the patent records.

These documents provide an opportunity to examine the invention’s origins, the biological reasoning behind it, the experimental observations described by the inventor, and what can be established about its subsequent development.

The Patent That Started the Investigation

The principal document is US10201563B2, Method of Treating Sinusitis, Including Chronic Sinusitis. The patent identifies Howard M. Alliger as inventor and Sinox Pharma, Inc. as assignee. Its priority date is January 19, 2010. The corresponding United States application was filed November 25, 2015, and the patent was granted February 12, 2019.

The invention had already entered the international patent system years earlier through WO2011090932A2, published July 28, 2011. Other records include the earlier American application US20130108714A1 and Canadian patent CA2787512C.

These documents belong to the same underlying invention family. They represent its development through different patent offices, rather than independent scientific discoveries. The central invention concerns exposing affected sinus and surrounding tissues to chlorine dioxide-containing compositions, with particular attention to chronic sinusitis.

Why Chronic Sinusitis Was an Interesting Research Target

Chronic rhinosinusitis is a complex inflammatory condition involving the nose and paranasal sinuses. Symptoms may include nasal obstruction, mucus accumulation, facial pressure, and impaired sense of smell.

Although microbial infections can contribute to some cases, chronic rhinosinusitis is not simply a persistent bacterial infection. Its development may involve impaired mucociliary clearance, allergies, inflammatory responses, nasal polyps, and changes in the microbial communities associated with sinus tissues.

Biofilms have also received attention in chronic sinusitis research. A biofilm is a structured community of microorganisms embedded within a protective extracellular matrix. Biofilm-associated organisms can behave differently from free-floating microorganisms, potentially complicating treatment and contributing to persistent disease.

Alliger’s patent specifically discusses biofilms, fungal involvement, mucus accumulation, and inflammatory processes.

The inventor’s underlying question was whether a chemical agent already known for antimicrobial activity in industrial and environmental settings might have useful properties when applied to tissues associated with chronic sinusitis.

The Inventor’s Background in Chlorine Dioxide Chemistry

The sinusitis patent was not Alliger’s first involvement with chlorine dioxide. An earlier invention, US4084747A, Germ Killing Composition and Method, was granted in April 1978. Another patent, US6039934A, Use of Xanthan Gum for Gelling ClO2 and Related Species, was granted in March 2000.

These earlier documents establish that Alliger had pursued chlorine dioxide-related inventions for decades before the sinusitis patent.

The 2000 patent addressed formulation technology, particularly the use of xanthan gum to produce gelled compositions involving chlorine dioxide and related chemical species. This background helps explain why the later sinusitis invention devoted substantial attention to formulation chemistry, stability, and delivery.

The inventor was not simply proposing that an existing industrial disinfectant be transferred unchanged into a medical setting. The patent describes attempts to adapt chlorine dioxide-containing compositions to the particular challenges of biological tissue exposure.

DIY Chlorine Dioxide Kit

The Proposed Role of Chlorine Dioxide

The sinusitis patent describes several possible mechanisms through which chlorine dioxide might affect the condition.

The first is antimicrobial activity.

Chlorine dioxide is an oxidizing agent capable of reacting with susceptible biological molecules. Its established use in water treatment and industrial disinfection provided a starting point for the inventor’s reasoning.

The second proposed mechanism involves mucus and biofilms.

Alliger suggested that chlorine dioxide’s chemical characteristics might allow it to interact with microbial communities protected by mucus or biofilm structures.

The third proposed mechanism involves inflammatory mediators.

The patent discusses cytokines, eosinophils, and other components of inflammatory responses, proposing that chlorine dioxide might alter some of the chemical processes contributing to sinus discomfort.

These ideas are not equivalent. Antimicrobial activity can be investigated through laboratory measurements of microbial survival. Biofilm disruption requires experiments examining organized microbial communities and their protective matrices. Effects on inflammation require measurements involving immune cells, inflammatory mediators, tissue responses, or clinical symptoms.

The patent brings these possibilities together as part of the inventor’s proposed explanation, but they require different kinds of experimental evidence.

Biofilms: One of the More Interesting Hypotheses

The patent’s discussion of biofilms is particularly relevant to the history of chronic sinusitis research. Alliger noted that chlorine dioxide had long been used in industrial settings to address microbial films in water-handling systems. He proposed that similar chemical properties might be relevant to microbial biofilms associated with nasal passages.

This is an example of transferring a research question from one field into another.

Industrial biofilms and biofilms associated with living tissues share certain structural characteristics, but they exist under very different conditions.

A chemical capable of disrupting biofilms in pipes or water systems does not necessarily have the same behavior when exposed to mucus, proteins, living epithelial cells, and the immune environment of human tissue.

The patent’s significance is that it identifies biofilm disruption as a potential research direction.

Determining whether a particular chlorine dioxide formulation could selectively affect sinus-associated biofilms would require experiments involving relevant microbial species, tissue models, and clinical outcomes.

What the Patent Reports About Human Observations

One of the most revealing portions of the patent appears in its discussion of how the inventor developed the proposed treatment.

Alliger describes personal experimentation involving chlorine dioxide-containing mouthwash formulations. According to the patent, observations during gargling led him to investigate effects involving the throat, nasal passages, and sinus drainage.

The inventor reports experiencing changes in nasal congestion and mucus clearance, which prompted further exploration of localized applications.

The patent also describes observations of temporary irritation and the inventor’s efforts to identify formulations he considered more tolerable.

These passages are useful historical evidence because they describe the apparent origin of the invention. However, the reported observations are presented as the inventor’s experience and development narrative. They are not accompanied by a controlled clinical dataset establishing treatment efficacy.

The document does not provide a clearly defined clinical population, randomized comparison groups, standardized symptom assessments, or independently adjudicated outcomes for the claims of sinusitis improvement.

This distinction does not erase the observations. It identifies their evidentiary status. They are inventor-reported findings that may have helped generate a hypothesis, rather than independently verified clinical results.

What the Patent Actually Claims

The granted American patent contains 28 claims. Its principal claim concerns chlorine dioxide-containing compositions proposed for treating, inhibiting, or reducing the likelihood of sinusitis.

The dependent claims describe different formulations and routes of localized exposure. These include applications involving nasal membranes, the upper mouth, gargling, aerosols, and other delivery concepts. The invention therefore extends beyond a conventional mouthwash. It concerns a proposed method of bringing chlorine dioxide-containing compositions into contact with tissues associated with the upper respiratory system.

The breadth of the claims reflects the inventor’s attempt to protect different implementations of the underlying idea.

Patent claims, however, describe the scope of an invention for which legal protection is sought or granted. They are not equivalent to the results of clinical trials.

International Patent Development

The invention’s patent history provides another useful perspective. The earliest priority filing dates to January 2010. An international application followed in January 2011, with publication in July of that year. An American application was published in 2013, while a later continuation application was filed in 2015. The resulting American patent was granted in February 2019.

The international application is recorded as ceased, and the earlier American application as abandoned. The later United States patent is recorded as active in the patent database consulted.

The presence of both abandoned applications and a granted continuation is not unusual in patent prosecution. It illustrates how an inventor may revise or continue claims over time while pursuing protection for the underlying technology. The Canadian patent record provides additional evidence that protection was sought beyond the United States.

The Commercial Development Connection

An especially interesting development appears in a 2020 scientific article discussing acidified sodium chlorite-derived chlorine dioxide preparations for nasal and oral applications.

The article is titled: Acidified Sodium Chlorite Solution: A Potential Prophylaxis to Mitigate Impact of Multiple Exposures to COVID-19 in Frontline Health-Care Providers, published in Hospital Practice, the paper discusses the possibility of investigating chlorine dioxide-containing preparations as an approach to reducing exposure-related infection risks.

Among the products mentioned is Snoot, identified as a formulation associated with Sinox Pharma, Inc. This is a noteworthy connection. The patent record identifies Sinox Pharma as the company associated with Alliger’s sinusitis invention. The later publication identifies a commercially available nasal preparation associated with the same company.

The evidence therefore supports a connection between the patent development program and a product that was discussed in subsequent scientific literature. It does not, by itself, establish the product’s regulatory classification, current commercial availability, or clinical effectiveness.

What About Human Tolerability Data?

The 2020 article refers to tolerability information supplied by Sinox Pharma. The authors describe company-held data from 2017 concerning nasal exposure to a chlorine dioxide-containing formulation.

The distinction is important: these data were described as being on file with the company, rather than published as a complete, independently accessible clinical study.

The article also acknowledged the absence of published human intranasal findings at that time.

Consequently, the publication establishes that tolerability observations were reportedly collected or held by the company, but it does not provide enough information to independently evaluate their methodology, sample size, or results.

Obtaining the original study documentation would be a useful next step for researchers investigating the product’s development history.

A Related Clinical Research Direction: Hypochlorous Acid

A separate clinical trial published in 2016 investigated low-concentration hypochlorous acid nasal irrigation in patients with chronic rhinosinusitis. The study enrolled 43 adults and compared hypochlorous acid irrigation with saline over eight weeks. The investigators reported improvements in some symptom measurements among participants receiving hypochlorous acid.

Low-Concentration Hypochlorous Acid Nasal Irrigation for Chronic Sinonasal Symptoms: A Prospective Randomized Placebo-Controlled Study. This study is relevant to the broader history of oxidizing antimicrobial formulations investigated for sinonasal conditions. However, hypochlorous acid and chlorine dioxide are chemically distinct substances.

The trial therefore cannot be used as direct clinical corroboration of Alliger’s chlorine dioxide invention. Its relevance is that it documents independent clinical interest in another oxidizing formulation for chronic sinonasal symptoms.

That comparison may be useful to researchers examining the wider development of topical antimicrobial approaches.

What Happened After the Patent?

The available records establish several developments. Alliger’s chlorine dioxide-related patent history extends back to the 1970s. The sinusitis invention entered the patent system in 2010. International and American applications followed.

A United States patent was granted in 2019. A 2020 scientific publication identified a Sinox Pharma nasal formulation and referred to company-held tolerability information.

These findings demonstrate that the invention progressed beyond an isolated patent filing into at least some form of product development and subsequent scientific discussion.

What remains less clear is whether Sinox Pharma conducted formal controlled clinical trials specifically evaluating chlorine dioxide for chronic sinusitis.

The sources examined for this article did not establish the existence of a published randomized trial of the patented chlorine dioxide formulation. Nor did they establish whether independent researchers reproduced the inventor’s reported observations. Those questions remain appropriate subjects for further investigation.

Chlorine Dioxide for Humans
Chlorine Dioxide for Humans

Questions Worth Pursuing

Several lines of inquiry could help complete the historical record.

The first concerns Sinox Pharma’s unpublished 2017 tolerability information. Access to the original report could clarify its design, population, observations, and conclusions.

The second concerns product development. Additional records might establish whether the commercial formulation underwent formal performance testing, regulatory review, or clinical investigation.

The third concerns biofilms. Laboratory research using sinus-associated microbial biofilms could help determine whether the inventor’s proposed mechanism was subsequently investigated.

The fourth concerns inflammation. The patent’s discussion of cytokines and eosinophils raises mechanistic questions that would require direct experimental measurements.

Finally, patent citation records may identify later inventions that built upon or distinguished Alliger’s work. Together, these questions offer a path toward understanding how far the original invention progressed beyond its patent disclosures.

Conclusion

Howard M. Alliger’s sinusitis patent represents a documented American effort to investigate chlorine dioxide-containing formulations for localized upper-respiratory applications.

The invention emerged from decades of the inventor’s earlier work involving chlorine dioxide chemistry and formulation technology. Its central hypothesis concerned whether chlorine dioxide’s oxidative properties could be adapted to conditions involving sinus inflammation, microbial activity, mucus accumulation, and biofilms.

The patent describes inventor-reported observations and proposes several biological mechanisms, although the document does not provide controlled clinical evidence establishing the proposed treatment outcomes.

The subsequent appearance of a Sinox Pharma nasal formulation in a 2020 scientific publication adds an important development to the historical record.

It shows that the research direction extended beyond the original patent application and into a commercially identified formulation discussed in scientific literature.

At the same time, the available documents leave several questions unresolved, particularly regarding independently published human studies, biofilm experiments, and the clinical development history of the patented approach.

For researchers investigating chronic rhinosinusitis, antimicrobial chemistry, biofilms, or the history of pharmaceutical inventions, the patent and its associated records provide a useful collection of primary documents and leads for further investigation.

Primary Sources and Further Reading

  1. United States patent, granted 2019

US10201563B2: Method of Treating Sinusitis, Including Chronic Sinusitis

Inventor: Howard M. Alliger. Assignee: Sinox Pharma, Inc.

  1. International patent application, published 2011

WO2011090932A2: A Method of Treating Sinusitis, Including Chronic Sinusitis

Priority date: January 19, 2010.

  1. United States patent application, published 2013

US20130108714A1: Method of Treating Sinusitis, Including Chronic Sinusitis

Earlier American application in the same invention family.

  1. Earlier chlorine dioxide invention, granted 1978

US4084747A: Germ Killing Composition and Method

Inventor: Howard M. Alliger.

  1. Formulation patent, granted 2000

US6039934A: Use of Xanthan Gum for Gelling ClO2 and Related Species

Inventor: Howard M. Alliger.

  1. Scientific publication, 2020

Acidified Sodium Chlorite Solution: A Potential Prophylaxis to Mitigate Impact of Multiple Exposures to COVID-19 in Frontline Health-Care Providers

Hospital Practice. Includes discussion of a Sinox Pharma formulation and company-held tolerability information.

  1. Related clinical trial, 2016

Low-Concentration Hypochlorous Acid Nasal Irrigation for Chronic Sinonasal Symptoms: A Prospective Randomized Placebo-Controlled Study

A study of hypochlorous acid, a chemically distinct oxidizing agent, included for comparative research context.

 

Chlorine Dioxide and Cataracts

 Could a Cloudy Lens Be Influenced by More Than What Is Happening Inside the Eye? At first glance, cataracts and chlorine dioxide seem like an unlikely pair. A cataract develops when the normally transparent lens of the eye becomes cloudy. Chlorine dioxide is best known as an oxidizing antimicrobial used in water treatment and disinfection. Yet Herb Roi Richards included cataracts among the conditions discussed in his field work with chlorine dioxide, and other figures in the chlorine dioxide community have explored very different approaches to eye health.

Long before the current chlorine dioxide movement, some physicians were also experimenting with DMSO and antioxidant compounds in people with cataracts and other eye conditions. Pasted text

Together, these observations raise an interesting question: What if a cataract is influenced by more than what is happening inside the cloudy lens itself?

Cataracts Are More Than a Cloudy Film

A cataract is not a film growing over the outside of the eye. The clouding occurs within the lens. The lens must remain remarkably transparent to properly focus light. Its proteins exist in a highly organized environment that must be maintained for decades. As those proteins become damaged or aggregate, the lens gradually loses transparency.

Age is the greatest risk factor, but cataract development can also be associated with diabetes, smoking, ultraviolet exposure, certain medications, trauma and oxidative damage. That makes cataracts more than a mechanical problem. They also involve the biological environment of the lens.

Oxidative Stress and the Lens

The lens has natural systems that protect its proteins from oxidative damage. Antioxidant defenses, including glutathione, play an important role in maintaining normal lens chemistry. As people age, the balance between oxidative stress and the lens’s ability to protect and maintain its proteins can deteriorate.

This does not mean that taking antioxidants will reverse an established cataract. It does, however, help explain why so much cataract research and natural eye-health literature focuses on oxidative stress, nutrition and antioxidant protection.

The collected material surrounding cataracts includes lutein and zeaxanthin, vitamin C, bilberry, curcumin, saffron, quercetin, resveratrol and other nutritional compounds investigated for various aspects of eye health. Pasted text Pasted text

These substances do not all have equal evidence behind them, and some of the research is preclinical. But collectively, they illustrate an important concept: Supporting the environment in which the lens exists may be as interesting as focusing exclusively on the cataract itself.

Diabetes Shows How an Upstream Problem Can Reach the Eye

Diabetes provides a particularly useful example.

Elevated glucose can alter the chemistry and metabolism of the lens. Changes within the lens can increase osmotic and oxidative stress and contribute to cataract formation.

The pathway might be simplified as:

POOR GLUCOSE CONTROL

↓

ALTERED LENS METABOLISM

↓

OXIDATIVE AND OSMOTIC STRESS

↓

PROTEIN DAMAGE

↓

LOSS OF LENS TRANSPARENCY

↓

CATARACT

Not every cataract is caused by diabetes. The importance of this example is that a problem occurring elsewhere in the body can influence what eventually becomes visible inside the eye.

This raises a broader question: Could improving an upstream biological condition sometimes influence what happens downstream in the lens?

An Earlier DMSO Connection

The historical material surrounding DMSO adds another dimension. According to a report presented to the American College for Advancement in Medicine (ACAM) in May 1980, an ophthalmologist described using DMSO in approximately 200 patients with several eye disorders, including macular degeneration, macular edema and traumatic uveitis. For cataracts, the physician reportedly used topical DMSO. Other physicians described formulations involving DMSO and superoxide dismutase, or SOD. Pasted text

These reports do not establish DMSO as a clinically proven cataract treatment. They are nevertheless historically interesting because they reflect an attempt to influence eye chemistry rather than viewing cataracts solely as an irreversible mechanical change.

DMSO has long attracted interest because of its ability to penetrate biological membranes and enhance the delivery of some substances. SOD, meanwhile, is an antioxidant enzyme involved in controlling reactive oxygen species.

Once again, several familiar themes appear:

  • oxidative stress
  • antioxidant defenses
  • biological delivery
  • lens chemistry

Herb Roi Richards’ Approach to Cataracts

Herb Roi Richards approached cataracts somewhat differently.

His field material describes an oral chlorine dioxide regimen combined with indirect vapor exposure near the face and supportive measures that included magnesium chloride, antioxidant-rich foods and other companion products. Pasted text

The significance of Herb’s approach is not simply what was being used. It is the way he apparently viewed the problem.

Rather than treating the cataract exclusively as something that needed to be acted upon directly, his approach included systemic support.

That fits a recurring question surrounding many of Herb’s observations:

Could the apparent destination of an improvement be different from its biological starting point?

Other Chlorine Dioxide Practitioners Took a Different Approach

Andreas Kalcker described an ophthalmic approach called “Protocol O,” involving a highly diluted CDS preparation with saline and optional DMSO. His material describes using the preparation for ocular and nasal conditions. Pasted text

Jim Humble also described a highly diluted activated MMS preparation intended as eye drops. Pasted text

These preparation instructions are not reproduced here. Products applied directly to the eye require careful control of concentration, pH, sterility, osmolarity and tissue compatibility. From an investigative standpoint, however, the differences are noteworthy.

Herb emphasized a largely systemic approach. Kalcker and Humble described direct ophthalmic approaches. Earlier DMSO practitioners experimented with local DMSO and antioxidant-related approaches.

Different methods were being used in pursuit of a similar outcome.

That raises another useful question: What, if anything, did these approaches have in common biologically?

Could the Biological Environment Be the Missing Piece?

Suppose that some reported improvements were genuine and objectively measurable. Several possibilities could then be investigated.

  • Oxidative stress might have changed.
  • Antioxidant defenses might have changed.
  • Glucose regulation might have improved.
  • Inflammatory conditions might have changed.
  • Lens metabolism might have changed.

Another intervention being used simultaneously might have produced the improvement. Or the person’s vision may have improved without the cataract itself substantially changing. That last distinction is especially important.

“I can see better” and “my cataract reversed” are not necessarily the same observation.

Visual acuity can change for multiple reasons. Demonstrating cataract reversal would require documenting an actual change in lens opacity.

N-Acetylcarnosine and the Search for Nonsurgical Approaches

The collected material also describes a 2002 study involving 49 people with cataracts. Twenty-six participants received eye drops containing 1% N-acetylcarnosine, while others received placebo drops or no drops. The reported results included improvements in visual acuity and glare sensitivity among treated participants. Pasted text

N-acetylcarnosine has not replaced cataract surgery as the established treatment for vision-limiting cataracts, and its effectiveness remains debated. Its importance to this discussion is broader.

Researchers have explored whether the biochemical environment of the lens can be influenced rather than assuming that nothing can be done until the lens is surgically replaced.

Nutrition and Cataract Research

Nutrition provides another example of this approach.

The collected material highlights colorful fruits and vegetables, including citrus fruits, tomatoes, carrots and dark leafy greens, in connection with cataract prevention and eye health. Pasted text

Lutein, zeaxanthin, zinc, selenium, riboflavin, taurine and quercetin also appear among nutrients discussed for supporting the eyes. Pasted text Vitamin C has likewise been studied in relation to cataract risk. Pasted text

Preventing cataracts, slowing their progression and reversing an established cataract are very different claims. Nevertheless, this research reinforces a central point:

The lens is living tissue influenced by the biological environment surrounding it.

The Chlorine Dioxide Paradox

Chlorine dioxide adds an unusual complication to the discussion. Chlorine dioxide is an oxidizer. Oxidative damage is involved in cataract formation.

At first glance, those facts seem contradictory. But biological oxidation is not a simple good-or-bad switch. Effects depend upon concentration, location, duration, molecular targets and the surrounding biological environment.

Chlorine dioxide also has selective reaction chemistry. It does not react equally with every biological molecule it encounters. What remains unknown is whether those characteristics translate into a beneficial effect on cataract biology.

The unanswered pathway might look something like this:

CHLORINE DIOXIDE

↓

UNKNOWN INTERMEDIATE EFFECT

↓

CHANGE IN THE BIOLOGICAL ENVIRONMENT

↓

LENS CHEMISTRY / OXIDATIVE BALANCE / PROTEIN STABILITY

↓

POSSIBLE CHANGE IN VISION OR CATARACT

The missing steps are precisely what need investigation.

Maybe the Eye Isn’t the Beginning of the Story

A cataract is visible in the eye, but the biological story leading to it may involve much more than the eye.

Glucose metabolism can matter. Nutrition can matter. Oxidative stress can matter. Antioxidant defenses can matter. Age, medications, ultraviolet exposure and other factors can matter.

This creates a useful framework for investigating reports involving chlorine dioxide without requiring the assumption that chlorine dioxide somehow directly “dissolves” a cataract.

Perhaps something upstream changed. Perhaps something local changed. Perhaps several things changed simultaneously. Perhaps chlorine dioxide had nothing to do with the improvement.

The way to distinguish among those possibilities is documentation.

What Changed First?

When someone reports that chlorine dioxide improved or reversed a cataract, the most useful next step is not simply collecting another testimonial. It is determining what actually changed.

  • Was the cataract professionally diagnosed beforehand?
  • What was its grade?
  • What was the person’s visual acuity?
  • Was glare sensitivity measured?
  • Was the lens photographed?
  • Was the person diabetic?
  • What was happening with glucose control?
  • What medications and supplements were being used?
  • Were nutritional changes made?
  • Was DMSO involved?
  • Was anything applied directly to the eye?
  • When did the improvement begin?
  • Did a subsequent ophthalmic examination confirm a change in lens opacity?
  • Did the improvement persist?

Those questions turn an interesting story into an investigable observation.

From Testimonials to Evidence

The chlorine dioxide community has accumulated many personal reports over the years. The next step could be considerably more useful than simply collecting more stories.

Imagine documenting a series of cataract cases with:

  • professional diagnosis before intervention
  • lens photographs
  • cataract grading
  • visual acuity
  • glare testing
  • relevant metabolic measurements
  • complete documentation of interventions

and appropriate follow-up measurements.

Several outcomes would be informative.

  • If people feel their vision improved but the cataract remains unchanged, that tells us something.
  • If cataract progression appears to slow, that tells us something different.
  • If objective lens opacity decreases, that becomes especially interesting.
  • And if another measurable biological change consistently occurs before the eye changes, it may reveal an upstream pathway worth studying.

The Observation May Be Right Even When the Explanation Is Incomplete

Herb Roi Richards worked extensively from field observations. People told him what happened. He compared their experiences, looked for recurring patterns and developed theories from what he observed. Some of those theories may ultimately prove correct. Others may not. But an incomplete explanation does not automatically make an observation worthless.

People sometimes observe the end of a biological chain before science understands its beginning or middle. That is why recurring reports are best treated neither as proof nor as something to dismiss automatically. They are opportunities to ask better questions.

Cataracts May Offer Another Window Into Chlorine Dioxide

Modern cataract surgery is highly effective and remains the established treatment when cataracts significantly interfere with vision. That does not mean the biology leading to cataract formation has been completely explored.

If cataract development involves oxidative stress, metabolism, nutrition, protein maintenance and other potentially modifiable biological processes, there is good reason to continue investigating those pathways. And if people using chlorine dioxide continue reporting unexpected changes in cataracts or vision, those reports can be documented much more carefully than they have been in the past.

  • Measure the lens.
  • Measure the vision.
  • Document the intervention.
  • Record the other variables.
  • Follow the timeline.

And ask the question that continues to surface throughout the investigation of chlorine dioxide:

  • What Changed First?

The most interesting discovery may not ultimately be that chlorine dioxide somehow “dissolves” cataracts. It may be that changing something elsewhere alters the biological environment in which the lens is struggling to remain clear.

If so, the cloudy lens may simply be the place where the change finally becomes visible.

 

Informational Notice: This article examines historical reports, practitioner observations and research questions concerning cataracts and chlorine dioxide. It does not establish chlorine dioxide, DMSO or other substances discussed here as treatments for cataracts. Direct application of non-ophthalmic preparations to the eye can cause injury. Cataracts and changes in vision should be evaluated by a qualified eye-care professional.

 

Chlorine Dioxide and Long COVID: Could It Be One Piece of a Much Larger Puzzle?

For some people, COVID-19 ends in a week or two. For others, it doesn’t. Months – or even years – later, they may still be dealing with fatigue, brain fog, sleep problems, shortness of breath, digestive trouble, dizziness, changes in heart rate, pain, anxiety, weakness, or an inability to tolerate activity the way they once could.

Today we call this broad collection of persistent problems Long COVID, or post-acute sequelae of SARS-CoV-2 infection (PASC). And there’s something important to understand right at the beginning: Long COVID may not be one thing.

Even the CDC describes it as heterogeneous, with possible underlying processes including organ damage, ongoing inflammation, microvascular dysfunction, autoimmunity, inadequate antibody response, and continuing viral activity associated with reservoirs inside the body.

That immediately raises an interesting possibility. Maybe looking for one thing that fixes Long COVID is asking the wrong question.

And maybe some of the unusual recovery stories being reported around chlorine dioxide deserve to be examined from that perspective. Not as proof. Not as a cure. But as clues.

Something Doesn’t Quite Fit the “One Problem, One Solution” Model

Among chlorine dioxide users, reports occasionally surface from people who say persistent problems following COVID improved after chlorine dioxide became part of what they were doing. Those stories are anecdotal. They don’t establish that chlorine dioxide treats Long COVID, and they certainly don’t tell us why somebody improved.

But something about the reports is interesting. Frequently, chlorine dioxide isn’t described as the entire answer.

People experiment with nutrition, enzymes, supplements, lifestyle changes, anti-inflammatory approaches, microbiome support, and other interventions. Sometimes something helps. Sometimes several things appear to help. Sometimes nothing does.

That messiness might actually make sense if Long COVID itself represents several overlapping disturbances.

A 2025 review of viral persistence in Long COVID describes possible connections among persistent SARS-CoV-2 material, immune dysregulation, vascular and coagulation problems, microbiome dysbiosis, brainstem/vagus signaling, and latent-virus reactivation.

That’s a lot of moving parts. And it suggests an entirely different way of investigating the chlorine-dioxide reports.

Instead of asking: “Does chlorine dioxide cure Long COVID?” perhaps we should ask: “If some of these reports represent genuine effects, where in this complicated pathway could chlorine dioxide possibly be doing something?”

First Suspect: Persistent Viral Material

One increasingly studied Long-COVID hypothesis involves SARS-CoV-2 – or pieces of it – remaining in the body after the acute infection has passed.

Researchers have reported viral nucleic acids, proteins, or other evidence of persistent viral material in tissues, blood, and feces in some people following infection. This has led researchers to investigate whether continuing viral reservoirs could keep stimulating the immune system and contribute to persistent symptoms.

This doesn’t mean everybody with Long COVID has a hidden active infection. And it certainly doesn’t mean every symptom is caused by spike protein. But persistent viral material is no longer a fringe idea. It’s a legitimate research target. And one location keeps appearing in this story.

Something Interesting Is Happening in the Gut

SARS-CoV-2 isn’t exclusively a respiratory story. The gastrointestinal tract can be involved during infection, and researchers have become increasingly interested in the gut as one potential location for viral persistence after the acute illness.

A 2024 review specifically examined gut-related viral persistence in Long COVID, proposing that continuing gastrointestinal disruption associated with viral persistence could contribute to symptoms throughout the body.

At the same time, researchers have repeatedly found differences in the intestinal microbiomes of people with Long COVID.

A 2025 review reported patterns including reduced microbial diversity, decreases in some beneficial short-chain-fatty-acid-producing organisms, and increases in several pro-inflammatory bacterial groups. Proposed downstream effects include altered intestinal barriers, systemic inflammation, immune signaling and changes along the gut-brain and gut-lung axes.

Suddenly, the gut isn’t merely where food gets digested. It becomes a possible intersection between:

    • persistent viral material,
    • microbial ecology,
    • immune activity,
    • inflammation,
    • metabolism,
    • and signaling to other parts of the body.

And that’s where our investigation took an unexpected turn.

What Happens If We Change the Gut?

There’s a wonderful way to test whether something is merely associated with a problem or might actually participate in it.

Change it.

That’s where fecal microbiota transplantation – FMT – becomes particularly interesting.

FMT essentially introduces a carefully screened donor microbial community into another person’s intestinal ecosystem. It is about as different from chlorine dioxide as an intervention could possibly be.

Yet it helps us ask exactly the question we’re interested in: Can deliberately changing the gut environment change symptoms of post-COVID illness?

Researchers have actually tried it.

The Long COVID FMT Experiment

A prospective study published in 2024 recruited 60 people with post-acute COVID syndrome and insomnia. Thirty received FMT at weeks 0, 2, 4 and 8. Thirty served as controls.

At 12 weeks, insomnia remission occurred in 37.9% of the FMT group compared with 10.0% of the control group.

Participants receiving FMT also showed improvements from baseline in measures of sleep quality, anxiety, and daytime sleepiness, along with a reduction in blood cortisol.

But here’s the detail that may be even more interesting.

The microbiomes of the people who responded to FMT became more similar to their donors.

That same pattern wasn’t seen in the nonresponders. No serious adverse events were reported in this small study.

Now, we need to keep our feet on the ground. This was a small, nonrandomized, open-label pilot study. It does not establish FMT as a cure for Long COVID. But it gives us something more interesting than another correlation.

Researchers deliberately changed the intestinal microbial ecosystem; some non-gastrointestinal symptoms changed, and successful responders showed measurable microbial changes.

That’s a clue.

And FMT Isn’t the Only Microbiome Approach Being Investigated

Recent reviews describe preliminary Long-COVID intervention studies involving probiotics, prebiotics, synbiotics, and FMT.

Reported improvements across these early studies have included symptoms involving fatigue, concentration, memory, gastrointestinal function, sleep and mood.

The evidence remains limited and heterogeneous, and causality hasn’t been settled. But microbiome-directed treatment has moved beyond being merely an interesting theory.

That gives us an important distinction: Science hasn’t established that changing the microbiome solves Long COVID. But researchers are already experimentally changing the microbiome to see whether Long-COVID symptoms move with it.

That’s an important step.

2-Part Chlorine Dioxide Kit

Now Let’s Bring Chlorine Dioxide Back Into the Room

This is where we need to be careful. There is currently no good human clinical evidence demonstrating: chlorine dioxide → favorable gut-microbiome change → Long-COVID recovery.

We shouldn’t draw that arrow. But we can certainly ask whether it exists.

Chlorine dioxide is antimicrobial. As we’ve explored elsewhere, microorganisms can show different susceptibility to it, and its effects depend heavily upon concentration, exposure, environment, and competing reactive material.

So perhaps the most interesting chlorine-dioxide hypothesis isn’t: “Chlorine dioxide travels around the body hunting spike protein.” It may be much farther upstream: Could chlorine dioxide exposure alter some part of the gastrointestinal microbial or chemical environment in a way that changes downstream immune, inflammatory or metabolic signaling?

We don’t know. But now there’s a reason to investigate the question. And FMT helped us find it.

Two Completely Different Approaches Pointing Toward the Same Door

There’s an almost amusing contrast here. FMT says: Change the microbiome by putting a different microbial community in.

The chlorine-dioxide hypothesis might say: Change the microbial or chemical environment already there.

Those approaches couldn’t look much more different. Yet both lead to the same fundamental question: Can changing the gut environment alter symptoms elsewhere in the body after COVID?

Preliminary human microbiome-intervention research suggests that question deserves serious attention. It does not establish chlorine dioxide as the appropriate way to make that change. That’s the experiment that hasn’t been performed.

What About Spike Protein?

This subject becomes confusing quickly because “spike protein” has become a catch-all explanation for almost everything following COVID. The reality is more complicated.

Persistent viral antigen is one serious research hypothesis, but Long COVID also involves investigations of autoimmunity, inflammation, vascular dysfunction, microbiome changes, nervous-system dysfunction, and residual organ injury.

So even if researchers eventually develop an effective way to reduce persistent viral antigen, that might not repair every downstream consequence that has already developed.

Again: There may be more than one domino falling.

Nattokinase: An Interesting Laboratory Clue

Another substance appearing frequently in post-COVID discussions is nattokinase.

This one has an intriguing piece of laboratory evidence behind it. Researchers exposed SARS-CoV-2 spike protein to nattokinase in laboratory cell preparations and found that the spike protein was degraded in a dose- and time-dependent manner.

That’s interesting. But notice exactly what it tells us. It demonstrates that nattokinase can degrade spike protein under those experimental conditions.

It does not establish that taking oral nattokinase removes persistent spike protein throughout a living human body or treats Long COVID.

That’s precisely the distinction we need throughout this investigation: Mechanism worth studying ≠ treatment already proven.

What About Nicotine?

Nicotine presents another developing hypothesis involving nicotinic acetylcholine receptors and the body’s cholinergic signaling system.

Research has investigated interactions between SARS-CoV-2 proteins and nicotinic receptors, and preliminary reports have explored transdermal nicotine in Long COVID.

But the popular Internet explanation that a 7 mg nicotine patch for seven days simply knocks spike protein off cells and cleans everything up goes considerably beyond the evidence currently available. Nicotine also has genuine physiological effects and isn’t appropriate for everyone.

So again we have: interesting biological hypothesis rather than established Long-COVID treatment.

Maybe the “Stack” Is Telling Us Something Else

This brings us back to those anecdotal reports.

    • Someone takes chlorine dioxide.
    • Someone else adds nattokinase.
    • Someone adds bromelain.
    • Someone changes diet.
    • Another works on the microbiome.
    • Another addresses deficiencies.
    • Someone improves.

Then everybody argues about which ingredient deserves the credit.

But what if that isn’t the most interesting lesson? What if improvement sometimes requires addressing different parts of the system?

Imagine Long COVID as a collection of interconnected pathways:

Persistent viral material
↓
continued immune stimulation

Gut dysbiosis
↓
altered microbial metabolites and signaling

Intestinal-barrier disturbance
↓
systemic immune effects

Inflammatory dysregulation
↓
persistent symptoms

Microvascular dysfunction
↓
circulation and oxygen-delivery problems

Autonomic dysfunction
↓
heart-rate, blood-pressure and neurological symptoms

Previous tissue injury
↓
problems that may remain even after the original trigger disappears

Suddenly, the observation that “one thing helped, but didn’t fix everything” isn’t particularly surprising.

Where Does Chlorine Dioxide Fit?

We don’t know yet. And that’s precisely why this subject deserves better research. Perhaps chlorine dioxide ultimately proves irrelevant to Long COVID. Perhaps it affects something upstream. Perhaps only a particular subgroup responds. Perhaps reported improvements result from something entirely different. Or perhaps chlorine dioxide affects the system for reasons its current advocates don’t yet understand.

Those are all legitimate possibilities. The mistake would be deciding which one is true before measuring it.

We Actually Have a Negative Chlorine-Dioxide Result

This deserves inclusion because good investigations don’t hide inconvenient results. A randomized clinical trial tested 0.01% aqueous chlorine dioxide mouthwash in people with mild COVID-19. Under the conditions studied, chlorine dioxide mouthwash did not significantly reduce salivary SARS-CoV-2 viral titers compared with placebo at 10, 30, or 60 minutes.

That’s useful information. But it answers a very narrow question. It doesn’t tell us whether chlorine dioxide affects the intestinal microbiome, a gastrointestinal viral reservoir, Long COVID, systemic inflammation, or any other proposed pathway discussed here.

We shouldn’t turn a negative mouthwash experiment into proof against all possible chlorine dioxide hypotheses. But neither should we ignore it.

That’s how investigation works.

Anecdotes Aren’t Proof – But They Can Tell Us Where to Look

There’s an unfortunate tendency to put anecdotal observations into one of two boxes.

Believe everything.

Or:

Throw everything away.

Neither approach is particularly useful. Anecdotes are terrible at establishing causation.

    • People recover naturally.
    • They change several things simultaneously.
    • They remember selectively.
    • Symptoms fluctuate.
    • Expectations matter.
    • Other treatments matter.

But repeated observations can still generate research questions. That’s how many investigations begin.

The responsible progression is:

Observation

↓

Hypothesis

↓

Measurable prediction

↓

Experiment

↓

Replication

↓

Conclusion

The mistake isn’t listening to anecdotes. The mistake is skipping everything between observation and conclusion.

So Let’s Design the Experiment

This is where things become fun. Suppose researchers recruited people with well-characterized Long COVID. Before any chlorine dioxide exposure, measure:

    • intestinal microbiome composition,
    • microbial diversity,
    • viral antigen or RNA where appropriate,
    • inflammatory markers,
    • intestinal-barrier markers,
    • immune markers,
    • symptom severity,
    • fatigue,
    • cognitive performance,
    • sleep,
    • autonomic function,
    • and quality of life.

Then randomize participants appropriately. Measure again during and after intervention.

Now we could ask:

    • Did the microbiome change?
    • Which organisms changed?
    • Did inflammatory markers move?
    • Did persistent viral markers change?
    • Did symptoms change?
    • Did biological changes correlate with clinical improvement?
    • Did anything worsen?

And perhaps most importantly:

    • Did responders have something biologically different from nonresponders before treatment began?

That could tell us far more than another thousand testimonials ever could.

The FMT Clue Changes the Question

This may be the most important part of our investigation. FMT doesn’t prove chlorine dioxide works. It does something more useful. It gives us an independent way of testing whether the pathway we’re interested in matters.

We started with reports of people improving after chlorine dioxide. Instead of assuming chlorine dioxide must somehow travel directly to every affected organ, we looked upstream. That led us toward the gut.

Then we discovered that researchers had independently manipulated the gut microbiome in people with post-COVID illness – and observed both microbial changes and clinical changes in a small prospective study.

That’s not confirmation. It’s triangulation. And triangulation tells us where another experiment might be worth conducting.

What We Know, What We’re Investigating, and What People Report

This may be the simplest way to keep everything straight.

What we know: Long COVID is real, heterogeneous, and can involve multiple biological systems. Researchers are investigating persistent viral material, immune dysregulation, vascular dysfunction, and microbiome changes as potential mechanisms.

What we’re investigating: The gut may participate in Long COVID through viral persistence, microbial dysbiosis, immune signaling, and gut-brain/gut-lung pathways. Preliminary microbiome interventions, including FMT, have produced encouraging findings that require larger controlled trials.

What people report: Some chlorine-dioxide users describe improvement in persistent post-COVID symptoms. Those reports haven’t established efficacy or mechanism.

The research question lies between those three statements.

Chlorine Dioxide for Humans
Chlorine Dioxide for Humans

Curiosity Without Getting Married to the Answer

This is where Herb Roi Richards‘ approach to experimentation has something useful to contribute – not as a medical protocol, but as an attitude toward investigation.

    • Pay attention.
    • Keep records.
    • Don’t assume more is better.
    • Don’t become so committed to one explanation that contrary evidence becomes invisible.
    • Don’t assume improvement proves your theory about why improvement occurred.
    • And use the resources available to you.

For Long COVID especially, significant cardiac, respiratory, neurological, vascular, and autonomic problems can occur, so persistent or serious symptoms deserve competent medical evaluation rather than experimentation alone.

Caution and curiosity can occupy the same room.

Maybe We’re Looking for Pathways, Not Miracles

Perhaps one day researchers will discover a single central mechanism tying most Long COVID together. Perhaps they won’t.

Current evidence suggests there may instead be several interacting pathways – and different people may have different combinations of them.

That changes how we should think about unusual recovery reports.

The question doesn’t have to be: “What cured this person?”

It can be: “What changed?” Then: “Where did it change?”

And finally: “Can we make that change happen again under controlled conditions?”

That’s where chlorine dioxide currently belongs in this story. Not at the finish line with a flag reading CURE. At the beginning of an interesting experiment.

Chlorine dioxide may prove irrelevant, important, helpful only for a subgroup, or useful for reasons its advocates currently misunderstand. We won’t know until somebody asks the question carefully enough to measure it.

And thanks to what researchers are beginning to discover about the gut, we may finally have a much better idea where to start looking.

A Note About the Evidence: The references below intentionally include established Long-COVID research, emerging mechanistic research, preliminary microbiome interventions, and exploratory studies. None establishes chlorine dioxide as a treatment for Long COVID. They are included because they help identify biological pathways—particularly viral persistence, the gut microbiome, immune signaling and related mechanisms—that could be investigated when evaluating anecdotal reports involving chlorine dioxide.

References & Further Reading

  1. Centers for Disease Control and Prevention. “Clinical Overview of Long COVID.” Updated March 9, 2026.
    A useful foundation for the article. CDC describes Long COVID as a heterogeneous condition potentially involving organ damage, dysregulated inflammation, microvascular dysfunction, ongoing viral activity associated with reservoirs, autoimmunity, and inadequate antibody responses.
    CDC: Clinical Overview of Long COVID
  2. Du, H., et al. “Mechanisms of Gut-Related Viral Persistence in Long COVID.” 2024.
    A particularly relevant review examining the hypothesis that persistent SARS-CoV-2 or viral material in the gastrointestinal system may contribute to Long COVID, including possible connections between the gut, inflammation, immune responses and systemic symptoms.
    Read the full review on PMC
  3. Lau, R.I., et al. “Fecal Microbiota Transplantation for Sleep Disturbance in Post-acute COVID-19 Syndrome.” Clinical Gastroenterology and Hepatology. 2024;22(12):2487–2496.e6.
    This is probably our article’s most intriguing reference. Sixty people with post-acute COVID syndrome and insomnia participated in a prospective, nonrandomized study. Insomnia remission at 12 weeks was 37.9% in the FMT group versus 10% among controls. Responders’ gut microbiomes became more similar to their donors, providing a particularly interesting biological correlate to the clinical changes.
    FMT and Post-COVID Insomnia — PubMed
  4. Jiang, X., et al. “Fecal microbiota transplantation alleviates mild-moderate COVID-19 associated diarrhoea and depression symptoms: A prospective study of a randomized, double-blind clinical trial.” Journal of Medical Virology. 2024;96(8):e29812.
    A separate randomized, double-blind investigation of FMT during mild-to-moderate COVID-19. This isn’t a Long-COVID treatment trial, so we shouldn’t present it as one, but it provides another experimental connection between manipulating the intestinal microbiome and COVID-associated symptoms.
    FMT Randomized Trial — PubMed
  5. “Long COVID and gut microbiome: insights into pathogenesis and therapeutics.”
    This review pulls together observational and intervention research concerning the microbiome and post-acute COVID syndrome. Particularly useful for our purposes, it discusses probiotics, prebiotics and FMT and notes that some intervention studies reported improvements in fatigue, memory, concentration, gastrointestinal problems, sleep and mood—while other controlled microbiome interventions did not significantly improve post-COVID symptoms. That mixed evidence is important.
    Long COVID and the Gut Microbiome — Full Review
  6. “Microbiome and Long COVID-19: Current Evidence and Insights.” 2025.
    Another useful recent review concluding that preliminary microbiome-directed interventions are encouraging but that evidence remains limited and heterogeneous. It is a good reference for our distinction between an exciting research pathway and an established treatment.
    Microbiome and Long COVID Review
  7. Taniguchi, Y., et al. “Degradative Effect of Nattokinase on Spike Protein of SARS-CoV-2.” Molecules. 2022.
    The laboratory study behind many nattokinase/spike discussions. Nattokinase degraded SARS-CoV-2 spike protein in transfected cell lysates in a dose- and time-dependent manner and also degraded cell-surface spike under the experimental conditions. Importantly, this was laboratory evidence, not a clinical demonstration that oral nattokinase clears persistent spike from people.
    Nattokinase and SARS-CoV-2 Spike — PubMed
  8. “Long COVID — a critical disruption of cholinergic neurotransmission?” 2025.
    An exploratory paper behind the nicotine/nicotinic-acetylcholine-receptor discussion. It includes a patient investigation and survey observations concerning low-dose transdermal nicotine. The results are provocative, but they don’t establish the popular claim that a particular nicotine-patch regimen simply “removes spike from cells.”
    Long COVID and Cholinergic Neurotransmission — PubMed
  9. Onozuka, D., et al. “A Multicenter, Randomized, Open-Label, Placebo-Controlled Clinical Trial of the Effect of Cetylpyridinium Chloride Mouthwash and On-Demand Aqueous Chlorine Dioxide Mouthwash on SARS-CoV-2 Viral Titer in Patients With Mild COVID-19.” Journal of Evidence-Based Dental Practice. 2024;24(4):102040.
    Worth including precisely because it didn’t produce a positive chlorine-dioxide result. In this small randomized study, 0.01% aqueous chlorine-dioxide mouthwash did not significantly reduce salivary SARS-CoV-2 viral titers versus placebo at the measured time points. It tested a local mouthwash intervention in acute mild COVID—not oral chlorine dioxide, Long COVID, gut reservoirs or microbiome effects—so its negative result should be interpreted within that scope.
    Chlorine Dioxide Mouthwash COVID Trial — PubMed

Informational Notice

This article explores emerging Long COVID research and hypotheses prompted partly by anecdotal reports involving chlorine dioxide. It does not establish chlorine dioxide, nicotine, nattokinase, FMT, or any combination of interventions as a treatment for Long COVID. Chlorine dioxide and sodium chlorite are reactive chemicals, nicotine has significant physiological effects, and FMT requires medical donor screening because infectious organisms can be transmitted. People experiencing persistent symptoms after COVID – particularly chest pain, breathing difficulty, fainting, neurological changes, abnormal heart rhythms, or other serious symptoms – should seek appropriate medical evaluation.

 

The Gut-Brain Connection Amidst Chlorine Dioxide and Parkinson’s

For years, people experimenting with chlorine dioxide have reported something that sounds almost impossible. Some people diagnosed with Parkinson’s disease say their tremors diminished. Others describe improvements in movement, rigidity, walking, balance, speech, or everyday function.

And among the strongest testimonials are people who say, in effect: “I had Parkinson’s. I was told I would have it for the rest of my life. Now it is gone.” Those are extraordinary claims. They are also anecdotes.

We don’t have controlled clinical trials demonstrating that chlorine dioxide treats, reverses, or cures Parkinson’s disease. We don’t have systematic before-and-after neurological examinations documenting these reports. And because people frequently make other changes at the same time, chlorine dioxide may receive credit for something it didn’t cause.

So why discuss the reports at all? Because while investigating them, we run into something remarkable. Scientists studying Parkinson’s disease are increasingly looking somewhere we might not have expected: the gut. And some of the newest research suggests that changing what happens in the gut may actually change measurable features of Parkinson’s disease.

That doesn’t prove anything about chlorine dioxide. But it gives us a fascinating new question to investigate.

Parkinson’s Is More Than a Tremor

Parkinson’s disease is a progressive neurological disorder involving the loss or dysfunction of dopamine-producing neurons, particularly within an area of the brain called the substantia nigra.

The familiar symptoms can include:

  • tremor
  • slowed movement
  • stiffness
  • balance problems
  • changes in walking
  • speech difficulties

But Parkinson’s extends far beyond movement. Sleep, smell, mood, digestion and the autonomic nervous system can also be involved.

Another important part of Parkinson’s biology is a protein called alpha-synuclein, often abbreviated α-synuclein. In Parkinson’s, abnormal forms of this protein can accumulate and aggregate within the nervous system.

For decades, it seemed logical to concentrate almost entirely on what was happening inside the brain. Then researchers began paying much closer attention to what had been happening to many patients before their hands ever started shaking.

Before the Tremor, There May Have Been a Gut Story

Constipation is extraordinarily interesting in Parkinson’s disease. Not simply because Parkinson’s patients frequently develop constipation. Sometimes constipation comes first.

A systematic review and meta-analysis involving more than 740,000 participants found that constipation was associated with more than twice the odds of subsequently developing Parkinson’s disease. Importantly, the association remained when researchers examined constipation occurring more than 10 years before Parkinson’s diagnosis.

Later research involving more than three million participants also found a significant association between constipation and prodromal Parkinson’s disease. That doesn’t mean constipation causes Parkinson’s. Most people with constipation won’t develop Parkinson’s.

But it raises a fascinating question: Why can a gastrointestinal problem appear years before the neurological disease becomes obvious?

Enter the Gut-Brain Axis

The gastrointestinal tract and brain aren’t two completely independent systems. The intestinal nervous system, immune system, microbial ecosystem and brain communicate continuously.

Scientists call this interconnected communication network the Microbiome–Gut–Brain Axis, and Parkinson’s researchers are now studying it intensely.

A 2024 review describes Parkinson’s as involving both the central nervous system and the enteric nervous system—the enormous network of neurons associated with the gastrointestinal tract. The authors emphasize that important questions remain unanswered, including exactly how early the gut becomes involved and whether it initiates disease in some patients.

More recent reviews investigate possible relationships among:

gut dysbiosis → intestinal barrier dysfunction → microbial metabolites → immune activation → inflammation → α-synuclein pathology → neuroinflammation

These are active areas of research rather than a completed explanation of Parkinson’s disease. Still, we have traveled quite a distance from thinking Parkinson’s is simply a problem isolated inside the brain.

Could Parkinson’s Sometimes Begin in the Gut?

This is where the story gets particularly interesting. Researchers have proposed that Parkinson’s may not begin in exactly the same place in everyone. One contemporary model describes two broad patterns:

Brain-First Parkinson’s

Pathology may begin primarily within the brain and subsequently spread through other parts of the nervous system.

Body-First Parkinson’s

Pathology may begin within the peripheral nervous system—including potentially the enteric nervous system—and subsequently progress toward the brain.

A 2024 review of the evidence found support for aspects of this model, including clusters of symptoms associated with the proposed body-first subtype, such as constipation, REM-sleep behavior disorder, and autonomic dysfunction. Some imaging and pathology findings support the model, while other evidence remains conflicting.

That’s an important qualification. We shouldn’t replace the old oversimplification — “Parkinson’s starts in the brain.” — with a new one — “Parkinson’s starts in the gut.”

A better statement is:

Parkinson’s may represent more than one biological pathway, and the gastrointestinal system may play an important role in at least some of them.

The Alpha-Synuclein Trail

Alpha-synuclein makes the gut-first hypothesis even more intriguing. Researchers are investigating whether abnormal α-synuclein can arise within the enteric nervous system and participate in a chain of events eventually involving the brain.

One proposed route involves the vagus nerve, an important communication highway connecting internal organs with the brain.

The proposed sequence looks something like:

intestinal disturbance
↓
microbiome changes
↓
intestinal inflammation / barrier dysfunction
↓
abnormal α-synuclein biology
↓
enteric nervous system
↓
vagal pathways
↓
central nervous system
↓
neuroinflammation and neuronal dysfunction

Current research reviews describe versions of this pathway, but the precise direction, triggers, and causal relationships remain under investigation. Then, in 2026, researchers did something particularly interesting.

What Happens If Researchers Actually Change the Gut Microbiome?

Rather than simply observing that people with Parkinson’s have different gut microbes, researchers conducted a randomized, double-blind phase 2 clinical trial involving 72 newly diagnosed Parkinson’s patients who had not yet received dopaminergic Parkinson’s medication.

One group received repeated fecal microbiota transplantation from donors. The comparison group received their own microbiota. Sixty-six participants completed the 35-week trial.

The donor-FMT group improved by an average 3.8 points on the UPDRS III motor examination, while the comparison group changed by +0.1 points. Constipation also improved substantially more in the donor-FMT group.

That’s interesting by itself. But the biological measurements make the study even more intriguing.

Researchers observed changes in the microbiome, improved measures of intestinal-barrier integrity and decreased phosphorylated α-synuclein in colon biopsies. Changes in Escherichia-Shigella abundance correlated with changes in colonic α-synuclein.

This does not mean FMT cures Parkinson’s. It was a relatively small, single-center phase 2 study. It needs independent replication, longer follow-up, and further investigation. But it demonstrates something extremely relevant to our question:

Changing the intestinal microbial ecosystem was followed by measurable changes in both gastrointestinal and Parkinson’s motor outcomes in a controlled human experiment.

That is considerably more compelling than simply discovering different bacteria in Parkinson’s patients.

Chlorine Dioxide Kit or CDS 3000
Chlorine Dioxide Kit or CDS 3000

Now Let’s Bring Chlorine Dioxide Back Into the Conversation

Chlorine dioxide has established antimicrobial and oxidative chemistry. What has not been established is that chlorine dioxide beneficially modifies the Parkinson’s microbiome or treats Parkinson’s disease. That’s the missing bridge.

But suppose, strictly as a research hypothesis, that some of the reports surrounding chlorine dioxide are genuine.

Instead of imagining:

chlorine dioxide → travels to the substantia nigra → repairs Parkinson’s

we might investigate something more like:

chlorine dioxide exposure
↓
?
↓
intestinal microbial environment
↓
intestinal barrier / microbial metabolites
↓
immune and inflammatory signaling
↓
α-synuclein-related biology
↓
gut-brain communication
↓
neurological manifestations

The enormous question mark is intentional.

We don’t know what’s happening there—or whether anything clinically useful is happening at all.

But now we have something scientists could actually test.

Antimicrobial Doesn’t Automatically Mean Beneficial

This distinction is particularly important.

Chlorine dioxide’s antimicrobial properties do not establish that it would improve a disturbed microbiome.

The intestinal microbiome contains enormous numbers of organisms participating in normal physiology.

Killing or suppressing microorganisms indiscriminately could potentially be detrimental.

So the hypothesis cannot simply be: Parkinson’s involves microbes + chlorine dioxide kills microbes = chlorine dioxide treats Parkinson’s. Biology isn’t that simple.

Researchers would need to determine whether chlorine dioxide exposure changes microbial composition at all under the conditions being reported—and, if so, which organisms and microbial functions change.

Then they would need to determine whether those changes affect intestinal permeability, metabolites, inflammatory signaling, α-synuclein biology, or anything else relevant to Parkinson’s.

Oxidation Creates Another Important Question

There’s another reason to resist an overly simple explanation. Oxidative stress is already implicated in Parkinson’s disease.

Therefore: Parkinson’s involves oxidative stress + chlorine dioxide is an oxidizer doesn’t logically lead to: chlorine dioxide fixes Parkinson’s. Quite the opposite could be possible depending on concentration, location, and biological context.

The useful research question is more specific:

Does chlorine dioxide’s chemistry produce an indirect biological change that could explain any of the reported neurological observations without causing offsetting oxidative injury?

That’s measurable.

Inflammation May Be Another Piece of the Puzzle

Neuroinflammation is another major area of Parkinson’s research. And once again, the gut may participate.

Microbial products can interact with the immune system. Intestinal-barrier dysfunction can change exposure to microbial components. Immune signaling can become systemic, and researchers are investigating how these processes interact with inflammation within the nervous system and α-synuclein pathology.

So if a chlorine dioxide-associated change were ever demonstrated, researchers shouldn’t measure only tremor. They should measure what happened upstream.

Chlorine Dioxide for Humans
Chlorine Dioxide for Humans

How Herb Roi Richards Interprets the Reports

Herb Roi Richards, author of Chlorine Dioxide for Humans: Recipes & Treatment, approaches Parkinson’s disease from a different direction.

Based on the reports and field experiences he has collected, Richards proposes that chlorine dioxide may help by breaking down what he describes as heavy metals, microbial waste, and other irritants affecting brain and nerve tissue. In his framework, reducing this burden allows the body’s neurological environment to regain balance, potentially allowing electrical signaling to function more normally and tremors to diminish.

It is an interesting hypothesis—but several parts of it have not been established scientifically.

There is evidence connecting Parkinson’s disease with environmental exposures, neuroinflammation, oxidative stress, gut microbial changes, and altered intestinal-barrier function. There is also substantial research investigating metals and environmental toxicants as possible contributors to Parkinson’s risk and pathology. But that does not scientifically establish that chlorine dioxide removes heavy metals from human neurological tissue or that an “oxidative cleanup” restores neuronal electrical signaling in Parkinson’s patients.

Richards’ explanation should therefore be understood as his working field model, rather than an established mechanism.

What makes the model interesting in light of emerging research isn’t necessarily the idea that chlorine dioxide travels into the brain and cleans it. The more intriguing possibility may again be upstream:

intestinal environment → microbial products → intestinal barrier → immune signaling → systemic inflammation → neuroinflammation → neurological function

If chlorine dioxide really does account for some of the reported changes, researchers could determine whether anything along that pathway changes before neurological improvement occurs.

What Herb Actually Recommends

Richards’ approach isn’t limited to chlorine dioxide. His Parkinson’s protocol combines chlorine dioxide with nutritional, mineral, topical, and lifestyle measures.

In Chlorine Dioxide for Humans, he describes an oral chlorine dioxide schedule involving activated drops taken repeatedly during the day, along with a diluted topical compress applied to the neck or spinal area. He also discusses magnesium chloride and gentle stretching, and lists companion products including aloe vera, apple cider vinegar, flaxseed oil, Lugol’s iodine, and Epsom-salt baths.

That distinction matters.

If someone following Richards’ program subsequently improves, scientifically, we cannot automatically say: “Chlorine dioxide did it.” There are multiple interventions occurring simultaneously.

Magnesium, for example, has established roles in normal neuromuscular and nervous-system physiology. Exercise and physical therapy also have established roles in maintaining mobility, balance, flexibility, and function in Parkinson’s disease.

Other components of Richards’ regimen have very different evidence bases and proposed purposes. Consequently, the complete protocol creates both an interesting observation and a scientific attribution problem.

One Protocol, Several Testable Questions

Rather than accepting or rejecting the entire package, researchers could separate it.

  • Did chlorine dioxide exposure change anything measurable?
  • Did the microbiome change?
  • Did inflammatory markers change?
  • Did gastrointestinal function change?
  • Did magnesium status change?
  • Did physical activity or flexibility improve?
  • Did medication requirements change?
  • Did objective Parkinson’s scores change?
  • And which change happened first?

That approach respects the observations without requiring researchers to accept Richards’ explanation beforehand.

“My Parkinson’s Is Gone” Is the Beginning of the Investigation

When someone reports that their Parkinson’s disappeared, it’s tempting either to celebrate the story as proof or dismiss it as impossible. Neither response teaches us very much. Instead, ask questions.

  • Was Parkinson’s formally diagnosed?
  • By whom?
  • How long had the person had it?
  • What symptoms were documented?
  • Was the person taking levodopa or another Parkinson’s medication?
  • Did medication change simultaneously?
  • What exactly improved?
  • Did tremor disappear?
  • Did bradykinesia improve?
  • Did rigidity change?
  • What happened to walking and balance?
  • Was improvement confirmed by a neurologist?
  • Did UPDRS scores change?

And most importantly:

  • Did the improvement last?

Those details transform a testimonial into the beginning of a case history.

Parkinson’s Disease Isn’t the Same as Parkinsonism

This distinction could prove extremely important when reviewing historical reports.

  • A person can exhibit tremor, rigidity, slowed movement, and walking difficulties without having idiopathic Parkinson’s disease.
  • Drug-induced parkinsonism, vascular parkinsonism, atypical parkinsonian disorders, and other neurological conditions can produce overlapping symptoms.
  • Essential tremor can also be mistaken by patients for Parkinson’s.

Consequently, reports should ideally be divided into categories:

    1. Neurologist-confirmed Parkinson’s disease
    2. Probable Parkinson’s disease
    3. Other diagnosed parkinsonism
    4. Self-reported Parkinson’s
    5. Diagnosis uncertain

If the dramatic outcomes concentrate primarily among people with uncertain diagnoses, that tells us something. If they remain among people with well-documented progressive Parkinson’s disease, that tells us something considerably more interesting.

The Testimonials Could Become Data

Suppose there really are hundreds—or thousands—of these reports accumulated through the chlorine dioxide community.

Don’t begin by trying to prove that chlorine dioxide cures Parkinson’s. Begin by organizing the observations.

A retrospective registry could record:

original diagnosis → duration of disease → original symptoms → medications → gastrointestinal history → constipation history → chlorine dioxide exposure → other interventions → time until reported change → objective neurological changes → medication changes → physician follow-up → duration of improvement

Then, obtain medical documentation where participants voluntarily provide it. That alone could reveal whether there’s actually a pattern.

Then Look for the Gut-First Signature

Here’s where this becomes particularly exciting. If researchers identified a group of unusually strong responders, they could ask:

Did these people have gastrointestinal symptoms years before Parkinson’s appeared?

  • Did they have longstanding constipation?
  • Inflammatory gastrointestinal problems?
  • Unusual microbiome profiles?
  • Evidence of altered intestinal permeability?
  • Particular microbial metabolites?
  • A phenotype resembling proposed body-first Parkinson’s?

Now we aren’t simply collecting testimonials. We’re testing a hypothesis.

Imagine the Prospective Study

The next step could be remarkably straightforward conceptually. Enroll people with carefully confirmed Parkinson’s disease.

Characterize them before anything happens.

Measure:

  • UPDRS motor scores
  • gait and movement
  • tremor
  • rigidity
  • cognition
  • smell
  • sleep
  • constipation and GI symptoms
  • medications
  • inflammatory biomarkers
  • microbiome composition and function
  • microbial metabolites
  • intestinal-barrier markers
  • α-synuclein biomarkers where validated and appropriate
  • adverse effects

Then distinguish participants according to likely disease phenotype. And use appropriate controls and blinding.

  • If nothing changes, we learn something.
  • If symptoms change without microbiome changes, we learn something.
  • If microbiome changes occur without neurological improvement, we learn something.

But if a reproducible sequence appeared —

microbiome changes first → intestinal/inflammatory biomarkers change → α-synuclein-related measures change → objective neurological function improves

— that would deserve serious attention.

Same Diagnosis. Different Roads?

This may eventually turn out to be one of the most important lessons. Just as osteoporosis can result from very different biological pathways, Parkinson’s disease may not be biologically identical in every patient.

Researchers are already exploring brain-first and body-first models. That could matter enormously when evaluating unconventional observations.

Perhaps an intervention could affect one pathway strongly while doing virtually nothing to another.

A clinical trial that lumps everybody together might see a weak average effect. A carefully stratified study might discover that a particular biological subgroup behaves differently. Or it might discover nothing at all. Either result advances our understanding.

Something May Have Happened Before the Brain

This investigation began with a difficult question: How could chlorine dioxide possibly make Parkinson’s disappear?

We still don’t know that it does. But we’ve discovered that the original question may be too narrow.

  • Parkinson’s pathology isn’t confined to the brain.
  • The enteric nervous system is involved.
  • Constipation can precede diagnosis by more than a decade.
  • The microbiome differs in Parkinson’s and is being investigated as part of disease biology.
  • Researchers are actively studying gut-first and brain-first Parkinson’s.
  • And now a randomized phase 2 human trial has shown that deliberately modifying the intestinal microbiome can be followed by measurable improvements in Parkinson’s motor symptoms, constipation, and biological markers in the colon.

None of that demonstrates that chlorine dioxide treats Parkinson’s disease. But it does something almost as valuable for an investigation: It gives us somewhere intelligent to look.

If repeated chlorine dioxide reports are merely coincidence, expectation, misdiagnosis, or another intervention receiving misplaced credit, careful investigation should reveal that. But if something reproducible really is happening, the microbiome–gut–brain axis gives researchers a plausible place to begin searching for it.

Not with: “Chlorine dioxide cures Parkinson’s.” But with: “What changed first?” And perhaps, before the tremor and long before anyone thought to look at the brain, there was already a story unfolding in the gut.

Selected Research & Further Reading

Zhang R, et al. Gut microbiota modulation via repeated donor fecal transplantation improves motor and gastrointestinal symptoms in drug-naïve Parkinson’s disease: a randomized phase 2 trial. Signal Transduction and Targeted Therapy, 2026. Seventy-two newly diagnosed, drug-naïve patients were randomized; donor FMT produced greater motor and gastrointestinal improvements at 35 weeks and was associated with microbiome, intestinal-barrier and colonic α-synuclein changes.

Adams-Carr KL, et al. Constipation preceding Parkinson’s disease: a systematic review and meta-analysis. Journal of Neurology, Neurosurgery & Psychiatry, 2016. Across nine studies and 741,593 participants, constipation was associated with subsequent Parkinson’s disease and could precede diagnosis by more than a decade.

The Gut-Brain Axis in Parkinson’s Disease, 2024. Reviews gastrointestinal dysfunction, enteric nervous-system involvement, gut α-synuclein, microbiome research and controversies concerning early gut involvement in Parkinson’s pathogenesis.

Brain-first vs. body-first Parkinson’s disease: An update on recent evidence, 2024. Reviews human imaging, clinical and pathological evidence for biologically different Parkinson’s trajectories.

The gut-brain axis in early Parkinson’s disease: from prodrome to prevention, 2025. Reviews early microbiome changes, intestinal inflammation, α-synuclein and experimental gut-directed approaches.

Parkinson’s disease and the gut-brain connection: unveiling pathways, mechanisms and promising therapies, 2025. Reviews microbiome–gut–brain mechanisms and emerging microbiome-directed therapeutic research.

 

Educational Notice

This article is for education and research discussion. Chlorine dioxide has not been clinically established as a treatment or cure for Parkinson’s disease, and inappropriate exposure can cause serious harm. Parkinson’s symptoms can also have multiple causes, and changes in symptoms should not be used as a reason to discontinue prescribed Parkinson’s medication without the clinician managing that treatment. The chlorine dioxide observations discussed here are presented as hypothesis-generating reports, not evidence of efficacy.

 

CDS 3000, Mixing, Timing, Food, Antioxidants, UTIs & More

After reading Chlorine Dioxide for Humans: Recipes & Treatment by Herb Roi Richards, readers sometimes discover that one answer leads directly to another question. What exactly does “repeat” mean when making CDS 3000? Should activated chlorine dioxide be allowed to sit before use? What happens when food or supplements are consumed around the same time? And when someone is interested in chlorine dioxide for a particular part of the body, does chlorine dioxide actually travel intact to that location?

Those are reasonable questions. They’re also an opportunity to distinguish between practical instructions described in Richards’ book, chlorine dioxide chemistry, and ideas that remain unproven in human medicine. Let’s take them one at a time.

What Does CDS 3000 Mean?

CDS generally refers to chlorine dioxide solution—chlorine dioxide gas dissolved in water. “3000” refers to a target concentration of approximately 3,000 parts per million (ppm). That is equivalent to approximately 3,000 milligrams of chlorine dioxide per liter of solution.

Richards describes a home-generation method in which chlorine dioxide gas is produced separately and allowed to dissolve into water. His instruction to “repeat the process” means performing his described generation process a second time on the same batch. It does not mean continually repeating it indefinitely until something visibly happens.

CDS 3000

CDS 3000 is available commercially, already distilled, processed, rated, and bottled appropriately.

But How Do You Know It’s Actually 3000 ppm?

This is where an important distinction belongs in the book’s explanation. Color isn’t an accurate concentration meter. Neither is smell. And “I performed the process twice” doesn’t analytically prove that the resulting solution contains exactly 3,000 ppm, but under pristine conditions, the water will have absorbed its natural maximum.

Actual chlorine dioxide concentration can be measured using an appropriate analytical test designed for the concentration range involved. So there are really two different statements:

Richards’ recipe: Repeat the described process once—that is, perform two generation cycles on the same batch.

Analytical chemistry: If knowing the actual exact concentration matters for some reason, measure it rather than assuming it from color, odor, or the number of repetitions. Over-the-counter test strips are available for general confirmation. That’s a much more useful answer than trial and error.

Is 3000 ppm Really the Maximum Water Can Hold?

This deserves clarification, too. Richards uses approximately 3000 ppm as the practical target concentration for the CDS preparation described in his book. It is better not to describe 3000 ppm as an absolute universal “natural holding limit” of water.

How much chlorine dioxide remains dissolved depends upon physical and chemical conditions. Temperature matters. Light matters. The container matters. Headspace matters. And chlorine dioxide is volatile, which is why an open container can lose it to the surrounding air. Therefore, your jar must be glass, well-sealed, with little excess headroom inside.

So CDS 3000 is best understood as the target concentration of this preparation, not a universal law saying water can never contain more than 3000 ppm chlorine dioxide.

Should Activated Chlorine Dioxide Sit Until the Smell Goes Away?

No, that would work against the purpose of generating chlorine dioxide. The odor exists partly because chlorine dioxide is volatile. According to Richards, if there is no smell, there is virtually no chlorine dioxide left.

If an activated solution is left exposed to air, chlorine dioxide can escape from the liquid as gas.

Waiting specifically for the smell to disappear therefore isn’t a useful way of determining that a preparation is “ready.” It may simply mean there is less chlorine dioxide remaining in the solution. There’s another consideration, however.

Concentrated chlorine dioxide vapor shouldn’t deliberately be inhaled. Respiratory exposure can be irritating. Don’t use smell as a concentration or safety test, and don’t deliberately inhale chlorine dioxide vapor.

2-Part Chlorine Dioxide Kit

Does Chlorine Dioxide Simply Become Salt After 30–35 Minutes?

This is another useful clarification. Chlorine dioxide is reactive and doesn’t remain unchanged forever. When it encounters substances with which it can react, it undergoes reduction and forms reaction products, importantly including chlorite and chloride, with chemistry depending upon the circumstances.

Documentation concerning food-processing applications similarly describes chlorine dioxide degrading during use and is simplified as, “After 30 minutes, it simply becomes salt.” Although, there isn’t a universal stopwatch at which every chlorine dioxide molecule suddenly becomes sodium chloride. This is more of a generalization, but it is basically useless at that point as a pathogen killer.

What About Food?

Here’s where Richards’ practical philosophy and chemistry overlap in an interesting way. Chlorine dioxide is an oxidizer. Food contains enormous numbers of compounds capable of participating in chemical reactions.

Consequently, Richards’ reasoning is that consuming chlorine dioxide together with food may give the oxidizer many substances with which to react before whatever intended effect a user is seeking. Taking chlorine dioxide concurrently with food could potentially waste that serving.

That’s a chemical rationale, not proof of a therapeutic protocol.

For ordinary water disinfection, of course, this isn’t relevant in the same way: the chlorine dioxide is being used to treat the water itself, according to the water-treatment product’s directions, and it is very efficient.

What About Antioxidants?

The name provides a clue. Oxidant. Antioxidant.

Richards recommends separating chlorine dioxide from concentrated antioxidant supplements because antioxidants are, by definition, substances capable of participating in oxidation-reduction chemistry. It is best to separate chlorine dioxide from most other products by at least one-half hour.

That doesn’t mean eating an orange suddenly creates a dangerous interaction. Nor does it establish a clinically validated waiting period. It means that if someone is experimentally seeking an oxidative effect, simultaneously introducing large amounts of reducing/antioxidant compounds could work against that objective.

Do You Have to Take It Exactly Every Hour?

Richards describes schedules involving repeated servings across a day. Those are Richards’ protocols. Clinical research has not established that chlorine dioxide should be applied to treat an infection or other illness, nor are any official timings or dosages established, except by experience.

Interestingly, controlled human studies do exist involving much lower concentrations of chlorine dioxide and related drinking-water disinfectants. One study administered 500 mL daily containing 5 ppm for 12 weeks and reported no clinically important physiological effects in the healthy male volunteers studied. Another controlled evaluation also reported no obvious undesirable clinical effects under the conditions studied. Those studies are useful toxicology information.

They do not validate higher-dose therapeutic protocols. That’s an important distinction.

Does Chlorine Dioxide Travel Through the Body Until It Reaches the Bladder?

The answer changes how we should picture chlorine dioxide inside the body.

It is probably misleading to imagine a chlorine dioxide molecule being swallowed, entering the bloodstream, traveling intact for 45–60 minutes, arriving at the bladder, and then conducting battle at that location. Chlorine dioxide is highly reactive and seems to kill pathogens until it self-reduces to sodium chloride.

Available pharmacokinetic research, much of it older and involving radiolabeled chlorine species in animals, shows absorption and distribution of chlorine-derived species, but that isn’t evidence that intact active chlorine dioxide simply circulates until reaching a chosen organ.

Plus, if it basically expires in 30 to 35 minutes, I would not make a claim that active chlorine dioxide reaches the bladder in 45–60 minutes. We don’t have evidence establishing that.

DMSO – 16 fl. oz.

What About DMSO for “Delivering” Chlorine Dioxide?

Richards discusses DMSO in his book because DMSO readily penetrates biological tissues and can enhance the penetration of some substances. Richards suggests that combining DMSO with chlorine dioxide safely “delivers chlorine dioxide directly” to the bladder or another internal organ by rubbing the diluted combination into and well around the target area for 8 minutes.

That is not an established drug-delivery system, but it reportedly works for Richards and thousands of others.

What About Chlorine Dioxide for a UTI?

A urinary tract infection can involve bacteria in the urinary system, but persistent symptoms can have several explanations. A urine culture can identify whether bacteria are actually present and often determine which antibiotic they’re susceptible to.

For recurrent UTIs, current urological guidance discusses options including cranberry, methenamine, vaginal estrogen for appropriate patients, and targeted antibiotic strategies. It also advises contacting a natural healthcare professional when symptoms aren’t improving because additional testing or different treatment may be necessary.

Chlorine dioxide and Silver Water have been successfully applied to combat UTIs, but this application is not recognized by the professional medical establishment.

Wayne’ Rowland’s Colloidal Silver Water

And What About Silver Water?

Richards and other natural-health practitioners have reported experiences using silver preparations for various microbial concerns. That’s part of their field experience. Hundreds or thousands of anecdotal testimonials regarding topical bladder and vaginal silver douche resolved UTI symptoms shouldn’t be presented as evidence that it eradicated a urinary infection. Rapid relief of local discomfort doesn’t demonstrate eradication of bacteria from the bladder.

That distinction is especially important because an untreated infection can sometimes ascend toward the kidneys. That is why most chlorine dioxide users continue their treatments long after symptoms cease.

The Bigger Lesson: Three Different Kinds of Information

Perhaps the easiest way to navigate Chlorine Dioxide for Humans is to recognize that discussions surrounding chlorine dioxide often contain three different categories of information.

  1. Established chemistry

Chlorine dioxide is an oxidizing agent. It has antimicrobial properties. It is volatile. It reacts with other compounds. Its concentration can be measured.

  1. Established applications

Chlorine dioxide has legitimatized uses in water treatment, food processing, sanitation, and other antimicrobial applications. FDA records, for example, document authorized food-contact antimicrobial applications at specified concentrations and conditions.

  1. Experimental or field applications

Richards’ protocols for internal wellness applications, disease-specific regimens, DMSO combinations, and similar practices belong here.

These may be interesting and useful observations and hypotheses. They shouldn’t be presented as though clinical medicine has already established them.

Chlorine Dioxide for Humans

Curiosity Works Better When We Measure

Herb Roi Richards’ work grew largely from observation, experimentation, and conversations with people using natural alternatives. That kind of observation can generate worthwhile questions. But there’s a wonderful advantage available to us when dealing with chemistry: We can measure things.

  • Instead of asking whether CDS “looks about right,” measure its concentration.
  • Instead of assuming exactly how long chlorine dioxide survives, study its reaction kinetics under the relevant conditions.
  • Instead of assuming when it reaches an organ, conduct pharmacokinetic research.
  • And instead of deciding from testimonials whether a disease protocol works, compare outcomes systematically.

That doesn’t diminish curiosity. It gives curiosity somewhere to go.

A Note About Medical Use

Chlorine Dioxide for Humans: Recipes & Treatment describes Herb Roi Richards’ protocols and field observations. Those protocols are not established medical treatments, and this page is intended to explain terminology and concepts rather than provide individualized dosing instructions. FDA continues to warn against drinking chlorine dioxide products marketed for treating disease and has claimed serious adverse events associated with some products and exposures.

Editorial note: Richards agrees with the FDA that drinking chlorine dioxide should never be considered. There is a world of difference between drinking a product and using a few drops of that product, like millions of people do every day. It is on record that chlorine dioxide is the greatest pathogen-killer known to man.

 

 

Are Chlorine Dioxide and Castor Oil Complementary Partners ?

Natural health has never been about finding one miracle product that solves every problem. Instead, many practitioners have long believed that different tools serve different purposes and may complement one another as part of a broader wellness philosophy.

That perspective is central to Herb Roi Richards’ book, Chlorine Dioxide for Humans: Recipes & Treatment. Throughout the book, Richards frequently mentions castor oil alongside chlorine dioxide—not because he viewed them as interchangeable, but because he believed each contributed something different to a person’s overall wellness routine.

In his view, chlorine dioxide and castor oil were teammates rather than competitors.

2-part Chlorine Dioxide Kit

Different Tools for Different Jobs

Richards often compared health to building a house.

A carpenter does not rely on a single tool to complete every task.

Likewise, Richards believed that no single wellness practice addresses every aspect of the human body. Instead, he encouraged readers to think in terms of complementary approaches that support one another.

Within that framework, chlorine dioxide was discussed primarily in relation to water purification and its oxidative properties, while castor oil was valued for its long history of traditional external uses and general body care.

Although the two were often mentioned in the same chapters, Richards did not describe them as doing the same thing. Rather, he viewed them as supporting different aspects of a broader personal wellness strategy.

A Long Tradition of Castor Oil

Castor oil has been used for generations in homes around the world.

Traditionally, people have incorporated it into personal care routines for purposes such as:

  • castor oil packs
  • skin moisturizing
  • scalp and hair conditioning
  • massage
  • softening scars and stretch marks
  • occasional laxative use when appropriate
  • general comfort for muscles and joints

These traditional uses have been passed from one generation to another for decades, helping castor oil maintain its place in many natural wellness traditions.

Why Richards Frequently Mentioned Both

Readers of Chlorine Dioxide for Humans: Recipes & Treatment will quickly notice that castor oil appears repeatedly throughout the book.

Richards discusses it alongside chlorine dioxide in chapters involving subjects such as:

  • aches and pains
  • arthritis
  • back discomfort
  • Bell’s palsy
  • bursitis
  • carpal tunnel syndrome
  • endometriosis
  • menstrual discomfort
  • respiratory infections
  • uterine fibroids
  • warts

He also highlights castor oil in discussions involving:

  • detox packs
  • hair and scalp care
  • joint and muscle support
  • moisturizing dry skin
  • scar and stretch-mark softening

These references reflect Richards’ personal wellness philosophy and the organization of his book. They should not be interpreted as established medical treatments for these conditions.

Chlorine Dioxide for Humans

Looking Beyond Individual Symptoms

One of the themes that runs throughout Richards’ writing is the idea that people are more than a collection of isolated symptoms.

Someone experiencing joint discomfort may also struggle with sleep.

Someone recovering from illness may also be dealing with muscle tension, dry skin, stress, or fatigue.

Rather than viewing these as unrelated problems, Richards encouraged readers to support the whole person through multiple healthy habits working together.

His philosophy included attention to hydration, nutrition, movement, sunlight, stress management, rest, and traditional wellness practices—including both chlorine dioxide and castor oil.

A Philosophy of Complementary Support

Perhaps the most interesting aspect of Richards’ work is that he rarely presented natural wellness as an “either-or” decision.

Instead, he consistently favored the idea that different practices may complement one another.

In that sense, chlorine dioxide and castor oil represent more than two individual products.

They illustrate Richards’ broader belief that health often improves through thoughtful combinations of supportive habits rather than dependence on a single solution.

Continuing the Conversation

As interest in complementary health continues to grow, Richards’ work invites readers to think beyond simple answers.

His writings encourage curiosity, careful observation, and personal responsibility while recognizing that many traditional practices remain topics of ongoing scientific discussion.

Whether readers ultimately agree with every conclusion or not, Chlorine Dioxide for Humans: Recipes & Treatment offers an opportunity to explore one practitioner’s integrated approach to natural wellness and the complementary role he believed chlorine dioxide and castor oil could play within that larger philosophy.

How Do You Use Chlorine Dioxide and Castor Oil?

Answer Below

Educational Notice

This article discusses Herb Roi Richards’ published wellness philosophy and summarizes themes from Chlorine Dioxide for Humans: Recipes & Treatment. It is intended for educational and informational purposes only. References to castor oil reflect its traditional uses, and references to chlorine dioxide reflect the author’s perspective. This article should not be interpreted as medical advice or as evidence that these approaches are established treatments for any disease or medical condition. Readers are encouraged to conduct their own research, review the available scientific literature, and consult qualified healthcare professionals when making decisions about their health.

 

Researching Blood & Lymphatic Disorders and Chlorine Dioxide

Blood and lymphatic disorders include a wide range of conditions that affect the body’s blood cells, bone marrow, lymph nodes, spleen, and immune system. Among the most serious are cancers such as leukemia and non-Hodgkin lymphoma, which can profoundly affect health, quality of life, and survival. Because these illnesses often require prolonged treatment and can be life-changing, some patients explore complementary and alternative approaches alongside conventional medical care. Chlorine dioxide has become one of the substances discussed in some alternative health communities, particularly through personal testimonials shared online.

While these anecdotal reports have generated interest, they do not establish that chlorine dioxide is an effective treatment for blood cancers or other blood and lymphatic disorders. To date, there is no high-quality clinical evidence demonstrating that chlorine dioxide safely or effectively treats leukemia, non-Hodgkin lymphoma, or related diseases.

What Are Blood & Lymphatic Disorders?

The blood and lymphatic systems work together to transport oxygen and nutrients, fight infection, remove waste products, and regulate immune function.

Disorders affecting these systems include:

  • Leukemia
  • Non-Hodgkin lymphoma
  • Hodgkin lymphoma
  • Multiple myeloma
  • Bone marrow disorders
  • Anemias
  • Clotting disorders
  • Certain immune system diseases

Many of these conditions are complex and require specialized diagnosis and treatment by hematologists and oncologists.

Leukemia

Leukemia is a group of cancers that begin in the bone marrow, where blood cells are produced. Abnormal white blood cells multiply uncontrollably, interfering with the body’s ability to produce healthy blood cells.

Symptoms may include:

  • Persistent fatigue
  • Frequent infections
  • Easy bruising or bleeding
  • Fever
  • Night sweats
  • Weight loss
  • Enlarged lymph nodes

Treatment often includes combinations of chemotherapy, targeted therapies, immunotherapy, radiation therapy, stem cell transplantation, and supportive care.

Non-Hodgkin Lymphoma

Non-Hodgkin lymphoma is a cancer of the lymphatic system involving abnormal growth of lymphocytes, a type of white blood cell.

Symptoms may include:

  • Enlarged lymph nodes
  • Fatigue
  • Fever
  • Night sweats
  • Unexplained weight loss
  • Persistent infections

Treatment varies depending on the specific subtype and may include chemotherapy, immunotherapy, targeted therapy, radiation, or stem cell transplantation.

Chlorine Dioxide 2-Part Kit

Why People Discuss Chlorine Dioxide?

People who discuss chlorine dioxide in relation to serious illnesses often describe personal experiences or testimonials that they believe reflect improvements in their health.

These reports may arise for many reasons, including:

  • Individual differences in disease course
  • Simultaneous conventional treatment
  • Supportive lifestyle changes
  • Differences in diagnosis
  • Natural variation in symptoms
  • Personal interpretation of improvement

Although such accounts can generate hypotheses, they cannot determine whether chlorine dioxide caused the reported outcomes.

What Properties of Chlorine Dioxide Are Often Discussed?

Chlorine dioxide is best known for its established uses as a selective oxidizing agent in:

  • Drinking water treatment
  • Municipal water disinfection
  • Food sanitation
  • Industrial sanitation
  • Biofilm management

Because of these antimicrobial and oxidizing properties, some people have speculated that chlorine dioxide could have broader biological effects. However, these hypotheses have not been demonstrated to translate into safe or effective treatment for blood cancers or lymphatic disorders.

Laboratory observations about chemical properties are not the same as evidence that a substance benefits patients with complex diseases.

Why Further Research Matters

History shows that patient observations have sometimes inspired scientific investigation. When large numbers of people report similar experiences, those reports may help researchers identify questions worth studying.

However, anecdotal reports alone cannot establish:

  • Safety
  • Effectiveness
  • Appropriate dosing
  • Which patients might benefit
  • Whether reported improvements were caused by the intervention

Answering those questions requires carefully designed laboratory research followed by well-conducted clinical trials that compare outcomes objectively.

Chlorine Dioxide for Humans

Leukemia and non-Hodgkin lymphoma remain serious diseases that require prompt medical evaluation and evidence-based treatment.

Although chlorine dioxide continues to be discussed in some wellness communities, there is currently no reliable clinical evidence demonstrating that it is an effective treatment for these disorders.

Continued scientific research into new therapies—including ideas generated from patient observations—plays an important role in advancing medicine. Any promising hypothesis should be evaluated through rigorous, ethical research designed to determine both safety and effectiveness before conclusions are drawn.

 

References

Blood & Lymphatic Disorders

National Cancer Institute (NCI).
Adult Acute Lymphoblastic Leukemia Treatment (PDQ®).
https://www.cancer.gov/types/leukemia

National Cancer Institute (NCI).
Adult Acute Myeloid Leukemia Treatment (PDQ®).
https://www.cancer.gov/types/leukemia

National Cancer Institute (NCI).
Chronic Lymphocytic Leukemia Treatment (PDQ®).
https://www.cancer.gov/types/leukemia

National Cancer Institute (NCI).
Non-Hodgkin Lymphoma Treatment (PDQ®).
https://www.cancer.gov/types/lymphoma

 

Blood Cancer Education

Leukemia & Lymphoma Society (LLS).
Educational resources on leukemia, lymphoma, myeloma, treatment options, and patient support.
https://www.lls.org

American Society of Hematology (ASH).
Patient education materials and clinical resources related to blood diseases and hematologic cancers.
https://www.hematology.org

 

Cancer Research

National Institutes of Health (NIH).
National research programs supporting cancer biology, immunology, and translational medicine.
https://www.nih.gov

National Center for Biotechnology Information (NCBI).
Biomedical literature, molecular biology databases, and scientific publications.
https://www.ncbi.nlm.nih.gov

PubMed.
Searchable database of peer-reviewed biomedical research.
https://pubmed.ncbi.nlm.nih.gov

 

Drinking Water & Chlorine Dioxide

U.S. Environmental Protection Agency (EPA).
Alternative Disinfectants and Oxidants Guidance Manual.
EPA 815-R-99-014.

U.S. Environmental Protection Agency (EPA).
National Primary Drinking Water Regulations and technical information on chlorine dioxide.

World Health Organization (WHO).
Guidelines for Drinking-water Quality.
Chemical Fact Sheets: Chlorine Dioxide and Chlorite.

 

Food Safety & Sanitation

U.S. Food and Drug Administration (FDA).
Food Code.

U.S. Department of Agriculture (USDA).
Food Safety and Inspection Service (FSIS) educational resources.

 

Scientific Background

American Water Works Association (AWWA).
Technical publications concerning chlorine dioxide in municipal drinking water treatment.

Water Research Foundation (WRF).
Research related to drinking water treatment technologies and microbial control.

 

Evidence-Based Medicine

Cochrane Library.
Systematic reviews evaluating healthcare interventions using rigorous evidence-based methods.
https://www.cochranelibrary.com

National Library of Medicine.
Resources on clinical research methodology, evidence evaluation, and biomedical literature.
https://www.nlm.nih.gov

 

Reader Note

This article is intended for educational purposes. Chlorine dioxide has established applications in water treatment, sanitation, and certain industrial processes. At present, there is no high-quality clinical evidence demonstrating that chlorine dioxide is a safe or effective treatment for leukemia, non-Hodgkin lymphoma, or other blood and lymphatic disorders. Readers should distinguish between personal testimonials, laboratory findings, and conclusions supported by well-designed human clinical studies.

 

 

The Chlorine Dioxide Challenge, and Pay Attention to Changes

There is a story that appears throughout Herb Roi Richards’ writing. Not because it proves anything. Not because he believed everyone had the same problem. But because he believed most people had stopped paying attention to themselves. Herb’s challenge was simple: If something appears safe, reasonable, inexpensive, and accessible to explore… observe what happens.

That challenge, which he first articulated in his book Lyme Disease Non-Medical Diagnosis And Treatment, became central to his personal story. And chlorine dioxide happened to become the symbol of that idea. Not because Herb thought chlorine dioxide explained everything. But because it was the thing he said made him begin asking different questions.

Herb’s Story Was Never Really About Chlorine Dioxide

If you read Herb carefully, something becomes obvious. His message was not: “This is the answer.” His message was closer to: “What if the answer is not where you’ve been looking?”

Years ago, Herb described living through years of chronic symptoms and frustration. Like many people with long-term unexplained illness, he described cycles of:

  • new symptoms
  • changing labels
  • periods of improvement
  • periods of regression
  • searching for explanations

His observation was not that diagnosis was useless. His observation was that labels can become sticky. People stop asking: What supports me? And start asking: Which disease do I belong to? That question changed his life.

The Experiment That Changed His Thinking

Herb eventually became interested in chlorine dioxide. Not because it was fashionable. Not because it was expensive. Actually the opposite. He described being attracted to something ordinary. Something simple. Something already widely discussed for water purification.

His thinking became:

  • If I explore something and nothing changes… I learned something.
  • If I explore something and something changes… I learned something.

The lesson was observation. Not certainty. Herb often framed his own experience as: “I noticed changes before I understood them.” That distinction is important.

 

The Real Challenge

People often misunderstand Herb’s invitation. They think he was saying: “Try chlorine dioxide and prove what disease you have.” But the deeper challenge appears to be: Try observing. Track patterns. Become impossible to fool.

  • If something helps: Notice.
  • If nothing changes: Notice.
  • If life improves: Notice.
  • If nothing happens: Notice.

That sounds simple. But very few people actually do it.

The Disease Chase

One of Herb’s recurring ideas was that many people become exhausted. Not necessarily because they are untreatable. But because they become trapped in endless pursuit.

New explanation. New specialist. New theory. New label.

Meanwhile:

  • sleep changes
  • environment changes
  • food changes
  • stress changes
  • movement changes
  • hydration changes
  • routines change

And nobody tracks any of it. Herb challenged that.

Meet the Winners

One of Herb’s most memorable ideas was what he called: The Winners

The Winners were not people who agreed with him. The Winners were people who stayed curious. People who experimented thoughtfully. People who kept notes. People who refused to stop participating in their own process. People who remained willing to say: That helped. Or that did absolutely nothing. Both answers counted. Because both moved them closer.

Why Chlorine Dioxide?

Whether someone agrees with Herb’s conclusions or not, chlorine dioxide remains important in his story for one reason: It represented permission. Permission to stop waiting. Permission to become observant. Permission to stop assuming that improvement must always arrive from somewhere outside yourself. Not because chlorine dioxide proves anything. But because curiosity starts somewhere. For Herb, that happened to be where the door opened.

So perhaps the challenge is not: Try chlorine dioxide. Maybe the challenge is: Try paying attention.

Become a student of your own patterns. Track what supports you. Track what doesn’t.

Remain humble. Remain hopeful. Remain curious. Because if there is one lesson Herb repeated over and over, it is this:

Sometimes people find progress in places they were never told to look.

You do not need to know the answer today. You do not need certainty. You do not need permission. You only need enough curiosity to ask:

What changes when I change something?

That question may not solve everything. But it might help you discover your next step.

FAQ

Q: What is the Chlorine Dioxide Challenge?

A: The challenge refers to the philosophy of observing personal changes and becoming more aware of patterns rather than relying only on assumptions.

Q: What does “pay attention to changes” mean?

A: It means tracking what shifts in your environment, habits, routines, and experience rather than assuming causes.

Q: Is self-observation the same as self-diagnosis?

A: No. Observation is noticing patterns; diagnosis is a medical process.

Q: Why do people become interested in wellness experimentation?

A: People often want to understand themselves better and become more active participants in their own health decisions.

Q: Who are “The Winners”?

A: In Herb’s framing, the Winners are people who stay curious, keep observing, and continue learning.

Disclaimer

This article discusses themes of self-observation and personal experimentation inspired by Herb Roi Richards’ writings and should not be interpreted as medical advice. Chlorine dioxide is widely used in water purification applications but is not presented here as a diagnosis, treatment, or cure for any medical condition. Symptoms and symptom changes should not be used to diagnose illness.

Chlorine Dioxide, Alcohol Use Disorder, Parasites, Neurology

For generations, Alcohol Use Disorder (AUD) has largely been viewed through two lenses. The first is the moral lens. The second is the psychological lens. In the moral model, a person drinks because they lack discipline, character, or self-control. In the psychological model, alcohol becomes a coping mechanism for trauma, stress, anxiety, depression, loneliness, or unresolved emotional pain.

While both perspectives may contain elements of truth, a growing number of researchers, practitioners, and independent investigators have begun exploring a third possibility: What if some forms of alcohol dependency have a biological component that extends beyond psychology alone?

That question has led some people into the emerging fields of microbiome research, parasitology, neuroinflammation, and microbial influence on behavior. And surprisingly, this is where chlorine dioxide enters the conversation.

Biological Hijacking

One of the more interesting ideas circulating among certain researchers is that some organisms may influence behavior in ways that increase their own survival. This sounds strange at first. Yet nature is full of examples. Numerous parasites are known to alter the behavior of insects, rodents, fish, and other animals in ways that benefit the parasite’s life cycle.

The question scientific researchers ask is:

Could certain organisms subtly influence human behavior as well?

Not necessarily through direct control, but through effects on:

  • dopamine pathways
  • serotonin regulation
  • reward sensitivity
  • inflammation
  • anxiety levels
  • craving patterns
  • stress responses

Some addictions may be amplified by biological factors operating beneath conscious awareness.

Toxoplasma gondii

One organism frequently discussed in these conversations is Toxoplasma gondii. T. gondii is a common protozoan parasite found throughout the world. While best known for its association with cats, exposure can also occur through contaminated water, undercooked meat, soil, and other environmental sources.

Researchers have investigated whether chronic T. gondii exposure may influence:

  • impulsivity
  • risk-taking behavior
  • reward seeking
  • reaction time
  • anxiety
  • mood regulation

The research suggests that parasites could influence reward circuitry, a finding that has captured considerable attention among those studying addiction.

Beyond Parasites

Interestingly, not everyone in this camp believes parasites are the entire story.

Some point instead toward:

  • fungal overgrowth
  • chronic mold exposure
  • gut dysbiosis
  • bacterial imbalance
  • inflammatory burden

The theory here is that certain microbes may influence cravings indirectly.

Some researchers have suggested that microbial populations may:

  • affect neurotransmitter production
  • alter gut-brain communication
  • increase cravings for sugar
  • increase cravings for alcohol
  • contribute to anxiety or depression

If true, alcohol consumption may sometimes be serving a biological demand rather than a purely psychological one.

Neuroinflammation and Self-Medication

Another idea frequently discussed involves neuroinflammation.

When chronic inflammation affects the nervous system, people may experience:

  • anxiety
  • depression
  • irritability
  • brain fog
  • sleep disturbances
  • emotional instability

Alcohol temporarily changes neurochemistry in ways that many people find calming.

Some investigators believe individuals may unknowingly use alcohol as a form of self-medication against chronic inflammatory discomfort.

In this framework, the alcohol is not the root problem. It is a symptom of a deeper imbalance.

2-part chlorine dioxide kit

Why Chlorine Dioxide Became Part of the Discussion

This is where chlorine dioxide enters the picture.

For decades, chlorine dioxide has been widely used in water purification and sanitation because of its ability to reduce a broad range of microorganisms.

Over time, individuals began experimenting with chlorine dioxide as part of broader wellness and microbial-reduction protocols, as chlorine dioxide is considered to excel in parasite destruction (e.g., Toxoplasma gondii), mold and fungal elimination, and microbiome recovery.

Among alternative-health communities, reports emerged from individuals who claimed reductions in:

  • alcohol cravings
  • compulsive drinking behaviors
  • binge patterns
  • obsessive thoughts about alcohol

The reports became common enough that entire communities formed around the discussion. What makes these reports particularly interesting is that many people describe similar experiences. Rather than feeling forced to stop drinking, they often describe the desire to drink gradually fading. Some compare it to turning down the volume on a constant internal signal.

The Most Commonly Reported Approach

Among those exploring this concept, one of the most frequently discussed methods involves very small amounts of activated chlorine dioxide taken throughout the day.

Users often describe:

  • small diluted servings
  • repeated at regular intervals
  • combined with hydration
  • nutritional support
  • mineral replenishment
  • gut restoration efforts

The reasoning is that maintaining consistent exposure may gradually reduce the microbial burden some believe contributes to addictive behavior.

Importantly, there is no universally accepted protocol, and approaches vary considerably from one individual to another.

Even within communities that support these ideas, there is broad agreement on one point: Alcohol Use Disorder is complex. Different individuals may be drinking for very different reasons.

Some may be primarily responding to:

  • trauma
  • grief
  • loneliness
  • emotional pain

Others may be dealing with:

  • neuroinflammation
  • microbial imbalance
  • chronic infection
  • gut dysfunction

And many may have a combination of both.

This may explain why some individuals report dramatic improvements.

A New Way of Looking at Addiction

Perhaps the most valuable contribution of these discussions is not chlorine dioxide itself. Perhaps it is the idea that addiction may sometimes involve more than willpower.

The emerging picture suggests that behavior may be influenced by a complex interaction between:

  • psychology
  • biology
  • environment
  • inflammation
  • nutrition
  • microbial ecology
  • and personal history

That possibility encourages a more compassionate view of those struggling with addiction.

Instead of asking:

“Why can’t they just stop?”

We may begin asking:

“What underlying forces are making it difficult for them to stop?”

Chlorine Dioxide for Humans Book

The connection between Alcohol Use Disorder, microbial burden, parasites, neuroinflammation, and chlorine dioxide remains an area of ongoing discussion and investigation. Some of the theories are supported by emerging research. Others remain speculative. Many are based largely on user reports and personal experiences. Nevertheless, the number of individuals exploring these ideas continues to grow.

Whether future research confirms or disproves these observations, the conversation raises important questions about how deeply biology may influence behavior and whether some forms of addiction are more complex than we have traditionally believed.

The most responsible path forward is continued research, careful observation, and a willingness to explore new ideas while maintaining critical thinking and intellectual honesty.

 

Disclaimer

This article is provided for educational and informational purposes only. Alcohol Use Disorder is a serious condition that may require professional medical, psychological, or addiction-related support. References to chlorine dioxide, microbial burden, parasites, fungi, or gut-related theories represent a mixture of emerging research, hypotheses, and anecdotal reports. Chlorine dioxide is widely used in water purification and sanitation applications but is not approved by regulatory agencies for the treatment of Alcohol Use Disorder or addiction. Readers should conduct independent research and consult qualified healthcare professionals regarding medical decisions.

 

Chlorine Dioxide, Gut Health and Anxiety Relief

It sounds almost absurd at first. How could something originally designed to purify water possibly have any effect on anxiety, panic attacks, emotional instability, brain fog, obsessive thinking, depression-like symptoms, or declining mental clarity? And yet, thousands of individuals experimenting with chlorine dioxide protocols have reported something unexpected: as their digestive systems improved, their emotional state often improved right along with it.

For many people, the shift was not subtle. Calmer thinking. Better sleep. Reduced panic. Improved emotional regulation. Greater mental clarity. Less “noise” in the mind. To some, this sounds impossible. But perhaps it only sounds impossible because most people were never taught how deeply connected the brain and gut truly are.

The Brain and the Gut Are Not Separate Systems

Modern science increasingly acknowledges what many natural-health researchers have suspected for decades: the digestive system and the brain are intimately connected. Some researchers even refer to the gut as the “second brain.”

The digestive tract contains enormous networks of nerves, neurotransmitters, bacteria, immune activity, and chemical messengers that directly influence mood, thinking, cognition, stress response, and emotional balance.

When the gut becomes chronically imbalanced, inflamed, overloaded, or hostile, the brain often reflects that imbalance.

People may experience:

  • Anxiety
  • Mood instability
  • Irritability
  • Depression-like symptoms
  • Brain fog
  • Poor concentration
  • Emotional volatility
  • Sleep disruption
  • Memory problems
  • Panic sensations
  • Cognitive decline

The relationship appears to work both ways.

Stress affects the gut. But gut dysfunction also appears capable of affecting the mind.

Many People Never Connect Digestive Problems to Emotional Problems

Someone may spend years treating anxiety while never considering the possibility that digestive imbalance could be contributing to the problem. Others may not even realize they have digestive dysfunction because they have lived with it for so long.

Bloating becomes “normal.”
Fatigue becomes “normal.”
Constipation becomes “normal.”
Mental fog becomes “normal.”
Emotional instability becomes “normal.”

Over time, the body adapts to chronic dysfunction until people forget what feeling truly well even felt like.

Many alternative-health advocates believe that chronic microbial imbalance, environmental stressors, inflammatory foods, toxins, poor digestion, and long-term gut disruption can create a cascading effect that eventually impacts neurological and emotional function. In this view, the brain is not failing independently. The brain is reacting to the environment the body is creating.

Why Chlorine Dioxide Helps

Chlorine dioxide has long been used around the world in water purification because of its ability to neutralize unwanted biological contaminants. Some natural-health experimenters believe this same property may help reduce certain burdens inside the body when used carefully and appropriately diluted.

Users frequently report improvements in areas such as:

  • Digestive comfort
  • Bloating
  • Gut regularity
  • Food tolerance
  • Energy
  • Sleep quality
  • Mental clarity
  • Emotional steadiness
  • Reduced anxious thinking

From their perspective, the emotional improvement is not mysterious at all.

If the gut environment improves, the brain may also improve.
If inflammation decreases, thinking may become clearer.
If microbial imbalance lessens, emotional regulation may stabilize.
If the body becomes less overwhelmed, the nervous system may finally relax.

To these individuals, chlorine dioxide is not acting as a psychiatric drug. Rather, they believe it may be helping remove stressors that were negatively influencing the entire system.

The Gut-Brain Axis May Be Far More Powerful Than We Realize

Researchers continue exploring the “gut-brain axis,” the communication network between the digestive system and the brain.

This relationship involves:

  • The vagus nerve
  • Neurotransmitters
  • Immune signaling
  • Inflammatory compounds
  • Hormonal regulation
  • Microbial metabolites
  • Stress chemistry

Interestingly, a large percentage of the body’s serotonin production is associated with the gut.

When digestive health deteriorates, emotional balance deteriorates as well. This does not mean every emotional disorder is caused by gut dysfunction. Human psychology is far more complex than that.

Trauma, grief, environment, stress, relationships, genetics, lifestyle, sleep, and countless other factors also matter deeply. But many people now believe digestive health is one of the most overlooked pieces of emotional and neurological wellness.

When Anxiety Is Not “Just in Your Head”

One of the most frustrating experiences for sufferers is being told their symptoms are “all psychological.”

Many individuals report very real physical sensations accompanying anxiety-related conditions:

  • Racing heart
  • Adrenal surges
  • Digestive distress
  • Skin sensations
  • Brain pressure
  • Dizziness
  • Disorientation
  • Fatigue
  • Cognitive impairment
  • Sensory overwhelm

Some alternative-health advocates argue these symptoms may sometimes reflect systemic stress within the body itself—not merely emotional weakness or faulty thinking.

In this framework, the body and mind are part of one interconnected system. When the body becomes overwhelmed, the mind may struggle to remain stable.

Some Believe Uncorrected Gut Dysfunction May Contribute to Cognitive Decline

A growing number of researchers are examining possible connections between chronic inflammation, metabolic dysfunction, microbial imbalance, and neurodegenerative decline.

Some natural-health advocates believe long-term digestive dysfunction may contribute to progressive cognitive conditions later in life. This remains an area of ongoing research and debate.

However, many people experimenting with gut-focused wellness strategies—including dietary changes, fasting, probiotics, detoxification approaches, and chlorine dioxide protocols—report improvements in clarity, focus, memory, and emotional regulation.

Some individuals even claim dramatic reversals of cognitive decline, though such claims remain controversial and are not universally accepted within mainstream medicine.

Why This Topic Creates So Much Resistance

Part of the resistance comes from the simplicity of the idea.

People often assume that powerful solutions must be expensive, patented, pharmaceutical, or technologically advanced.

The suggestion that improving internal biological balance could profoundly influence emotional and cognitive function challenges many deeply held assumptions. It also challenges the separation between “mental illness” and “physical illness.” Perhaps the two are not as separate as we once believed.

A More Holistic Way of Looking at Emotional Wellness

Many people are beginning to ask a deeper question: What if emotional suffering is not always purely psychological? What if, in some cases, the body itself is crying out for restoration?

This does not mean emotions are not real. It does not minimize trauma, hardship, loss, or psychological pain. But it may mean that supporting the body—especially the gut, nervous system, inflammation pathways, hydration, sleep, nutrition, and microbial balance—could play a much larger role in emotional stability than many people realize. And for countless individuals experimenting with chlorine dioxide protocols, that possibility no longer seems strange at all. To them, the results feel very real.

Important Note

Chlorine dioxide remains controversial when discussed for personal wellness applications. Regulatory agencies do not approve it for treating anxiety disorders, neurological disease, or mental-health conditions. Individuals interested in alternative wellness approaches should educate themselves carefully, proceed responsibly, and consult qualified healthcare professionals regarding any medical or psychological concerns.